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ABSTRACT 
In an attempt to provide further information on the molecular genetics of 
non-astrocytic gliomas and their histological correlation, we examined 61 
oligodendroglial and ependymal tumors (16 oligodendrogliomas, 12 anaplastic 
oligodendrogliomas, 7 oligoastrocytomas, 24 ependymomas and 2 anaplastic 
ependymomas) for mutations of the newly described PTEN/MMAC1 gene at 
10q23 and p53 gene using archival formalin-fixed paraffin-embedded tissues. 
Allelic deletions on chromosomal 10q23 and 10q25-26 regions, where 
PTEN/MMAC1 and DMBT1 are located, were also evaluated. For p53 gene, 
only 4 mutations were found in 3 oligoastrocytomas and 1 in an ependymoma. 
Interestingly, 3 out of 5 mutations were found in exon 4 which was only rarely 
screened for and no mutations have been reported previously. No mutations of 
the PTEN/MMAC1 gene were identified. The frequencies of allelic deletions at 
marker D10S2491 (which was mapped within PTEN/MMAC1), and between 
markers D10S209 and D10S587 (where DMBT1 gene was located) were found 
to be < 30% in both types of non-astrocytic gliomas. Nevertheless, high 
frequency of allelic deletions was detected at marker D10S215 (80%) at 
proximal 10q23 region in both oligodendroglial and ependymal tumors, and 
between markers D10S216 (42%) and D10S169 (67%) at distal 10q25-26 
region in oligodendroglial tumors. To further understand the significance ofthe 
prevalence of wild-type p53 gene in this series of tumors, we looked for 
amplification of the MDM2 gene. Only 1 ependymoma showed MDM2 
amplification and its p53 status was wild-type. It seemed from this study that 
mutations of the PTEN/MMAC1 gene, p53 gene, and amplification of the 
MDM2 gene do not play a major role in the pathogenesis or anaplastic 
• • 
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transformation of oligodendrogliomas and ependymal tumors. Mutations ofthe 
p53 gene appear to be restricted to oligodendroglial tumors with significant 
astrocytic differentiation, i.e. oligoastrocytomas. Amplification ofMDM2 gene 
is not a factor for p53 gene inactivation in different grades of oligodendroglial 
and ependymal tumors. With regard to the results on chromosome lOq, it is 
suggested that other unidentified glioma suppressor genes may be located at 
proximal region at marker D10S215 and/or the distal region of chromosome 
lOq. 





突膠質細胞瘤35例（WHO I I級1 6例，W H O III級12例，少突 





被克隆的腫瘤抑制基因P T E N / M M A C 1和D M B T 1的染色體位 
點。結果：共檢測到 5例 p 5 3 基因突變， 4例見於 3個少突 
星形混合膠質瘤中；另1例見於1個室管膜瘤中。値得一提的 
是， 5個 p 5 3基因突變中， 3個位於外顯子 4。 p 5 3外顯子 4 
的突變很少被硏究，文獻中也未見報道。61例腫瘤中無一例含 
PTEN/MMAC1基因突變�DNA片段丟失率在PTEN/MMACI基 
因位點 D10S2491，和 DMBT1 基因位點 D10S209 至 D10S587 
間 均 S 30%�而在PTEN/MMAC1基因D10S215位點近中間絲 
側，少突膠質瘤和室管膜瘤的DNA片段丟失率爲80% °此外， 
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m m : l , INTRODUCTION ‘ | 
I.1. Tumors of the Central Nervous System 
Tumors of the central nervous system (CNS) account for about 9% of 
all human cancers. The incidence of tumors of the CNS ranges from 10-17 
per 100,000 persons for intracranial tumors and 1 to 2 per 100,000 persons for 
intraspinal tumors. CNS tumors represent about 20% of all cancers of 
childhood, and 70% of these primary tumors arise in the posterior fossa, 
whereas in adults a corresponding proportion arises above the tentorium 
(Russell & Rubinstein，1989; Black, 1991; Burger, Scheithauer & Vogel, 
1991). 
In Hong Kong, the annual incidence of brain tumor has been reported 
to be between 2.2 to 4.2 per 100,000 population (Ho, Man & Chan, 1982; Ng 
et al., 1988), which is lower than that of the Caucasian population. Males are 
slightly predominant m malignant astrocytomas and pediatric 
medulloblastomas while meningiomas are more frequent in females. The 
types of brain tumors managed in our hospital between 1984-1992 were 
shown on Table L1. Gliomas, which accounted for 30%, appear to be the 
most common type of primary brain tumor in Hong Kong Chinese (Poon & 
Ng, 1992). 
The causes of brain tumors are not known and they can occur at 
any age. However, they are most common in children at 3-12 years old and at 
40-70 years old in adults. The most common type of primary brain tumors is 
gliomas and they begin in the glial tissue. Gliomas constitute approximately 
50% ofhuman primary brain tumors in Caucasian population. 
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Table I.1. Histological types of all brain tumors managed at the 
neurosurgical unit ofPrince of Wales Hospital, May 1984-
April 1992 (Poon & Ng，1992). 
Tumor type No. (%) 
Primary/Benign Meningioma 112 (20.0) 
Nerve sheath tumor 74 (14.0) 
Pituitary adenoma 47 (9.0) 
Haemangioblastoma 16 (3.0) 
Craniopharyngioma 13 (2.3) 
PrimaryMalignant Glioma 164 (30.0) 
Medulloblastoma 20 (4.0) 
Germ cell tumor 11 (2.0) 
Lymphoma 8 (1.0) 
Chordoma 3 (0.6) 
Neuroblastoma 2 (0.4) 
SecondaryMalignant Metastasis 72 (13.0) 
Others 4 (0.7) 
Total 546 , ( 1 0 0 ^ ) | iiii:iiiiililli;iiiilili 
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I.2. Histopathological Classification of 
Human Glial Tumors 
The gliomas are subdivided into astrocytic and non-astrocytic types 
(Table L2). The histopathology of these glial tumors is described below: 
L2.1. Histopathology of Astrocytic Gliomas 
Astrocytic gliomas are composed predominantly of neoplastic star-
shaped cells called astrocytes. Astrocytic gliomas are the most common type 
of gliomas and span a spectrum of malignancy, based on clinical and 
neuropathological criteria. They range from the benign, low-grade 
astrocytoma, such as the pilocytic astrocytoma, to an astrocytoma of an 
intermediate grade of malignancy, the anaplastic astrocytoma, and finally to 
the most malignant type, the glioblastoma multiforme (GBM) (Schmidek, 
1994). 
1.2.1.1. Diffuse Astrocytomas 
Diffuse astrocytomas are diffusely infiltrating tumors that are 
composed of well-differentiated neoplastic astrocytes. They comprise nearly 
75% of the astrocytic tumors and are prognostically unfavorable (Russell & 
Rubinstein, 1989). They preferentially arise in the cerebral hemispheres and 
have a wide range of histopathological features and biological behavior. They 
can be divided into the following clinicopathological entities: 
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Table I.2. Common types of gliomas in central nervous system. 
_ 广 養 、 ， … … ASTROCYTICTUMORS ^ ^1:¾¾;¾¾^¾ 
^ - ‘ 、 \、、•、、’ ’ ， ， ’ ’ ’. ‘,,,,, y:;A'i:ii,;mmm&m 
1. Diffuse astrocytoma 
2. Anaplastic (malignant) astrocytoma 
3. Glioblastoma 
4. Pilocytic astrocytoma 
5. Pleomorphic xanthoastrocytoma 
6. Subependymal giant cell astrocytoma 
OLIGODENDROGLLiL TUMORS iy«i»^ ^^  1iiliiiW 
. • . . . • • • -•  .... ... •.. • . .. ... .,‘.？.，."：.： :.,.X.,:.:,<.X.:.:h.:.:;:.X.,:.:.X.:.: :..:..:. ；•.：.• X.fe.：.：：.；.； ‘.:.,..；:::.:..::...:：.:.�:.:.:X:v;.,.,:;^ ;,X:;v:.^^  
1. Oligodendroglioma 
2. Anaplastic (malignant) oligodendroglioma 
3. Oligoastrocytoma 
4. Anaplastic (malignant) oligoastrocytoma 
EPENDYMAL TUMORS 
1. Ependymoma 
2. Anaplastic (malignant) ependymoma 
3. Myxopapillary ependymoma 
4. Subependymoma 
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Low-Grade Diffuse Astrocytomas 
Astrocytic neoplasms are characterized by a high degree of cellular 
differentiation and slow growth. Phenotypically, neoplastic astrocytes may 
vary considerably with respect to size, prominence and disposition of cell 
processes, and the abundance of cytoplasmic glial filaments (Kleihues, Burger 
& Scheithauer，1993). Mitotic activity is absent which may explain their slow 
growing behaviour. These lesions typically affect young adults with age 
between 30 and 40. The mean age of occurrence is 34 years and males are 
predominant (M:F ratio, 1.18:1). Due to the incomplete surgical resection, 
astrocytic gliomas almost always recur. They also have a tendency for 
malignant progression (Kleihues et al., 1997b). 
Anaplastic Astrocytomas 
They are the diffusely infiltrating astrocytomas with focal or dispersed 
anaplasia, and a marked proliferative potential, e.g. increased cellularity, 
pleomorphism, nuclear atypia and mitotic activity. Occasional proliferation of 
tumor vessels may occur (Kleihues, Burger & Scheithauer, 1993). Anaplastic 
astrocytomas may arise from low-grade astrocytomas, but may also be 
diagnosed at first biopsy, without indication of a less malignant precursor 
lesion. Such tumors often show a rapid tendency to progress, and ultimately 
transform to glioblastomas. The mean age at biopsy is 41 years and males are 
more frequently affected (M:F ratio, 1.87:1) (Davis, Kleihues & Burger, 
1997). 
Glioblastomas 
They represent the most malignant form of astrocytic tumors and are 
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composed of poorly differentiated, fusiform, round or pleomorphic cells and 
occasional multinucleated giant cells. Areas of vascular proliferation and/or 
necrosis are frequently observed (Kleihues, Burger & Scheithauer，1993). 
Glioblastomas may develop from low-grade diffuse or anaplastic astrocytomas 
(‘secondary glioblastomas'), but more frequently, they develop de novo 
(‘primary glioblastomas') without any evidence of a less malignant precursor 
lesion. There is a peak incidence with age between 45 and 70 years old, and 
the mean age at biopsy is 53 years. Males are more frequently affected (M:F 
ratio, 1.5:1) (Kleihues etal” 1997a). 
1.2.1.2. Others 
In addition to diffuse astrocytomas, there is another group of astrocytic 
tumors that is more circumscribed and shows a lesser tendency towards tumor 
progression and increasing anaplasia. These prognostically favorable varieties 
include pilocytic astrocytomas, pleomorphic xanthoastrocytomas and 
subependymal giant cell astrocytomas. However, they are less common as 
compared with diffuse astrocytomas. 
I.2.2. Histopathology ofNon-Astrocvtic Gliomas 
Non-astrocytic gliomas include oligodendroglial and ependymal 
tumors. Their histopathological classification is described below: 
1.2.2.1. 01 igodendroglial Tumors 
Oligodendroglial tumors include oligodendrogliomas, anaplastic 
oligodendrogliomas and oligoastrocytomas. These tumors constitute about 5 
to 15% of gliomas, and are most common in middle life. They preferentially 
affect the cerebral white matter and basal ganglia (Fumari, Huang & Cavenee， 
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1995). These tumors have a relatively good prognosis with a 5-year survival 
of approximately 80% (de Girolami, Anthony & Frosch, 1994). Their 
histopathology is discussed below: 
Oligodendrogliomas 
Oligodendrogliomas are composed predominantly of neoplastic 
oligodendrocytes. Microscopically, most oligodendrogliomas are moderately 
cellular. The tumor cells have uniformly round nuclei that are slightly larger 
than those of normal oligodendrocytes and are surrounded by a clear halo of 
cytoplasm (Figure Lla). They also show an increase in chromatin density but 
the mitotic activity is generally low. Calcification is also present in as many 
as 90% of these tumors (Kleihues, Burger & Schdthauer，1993). In general, 
patients with oligodendrogliomas have a better prognosis than those patients 
with astrocytomas. 
Anaplastic Oligodendrogliomas 
Oligodendrogliomas may progress to anaplasia, although less 
frequently than astrocytomas. Anaplastic oligodendrogliomas show focal or 
diffuse anaplasia, including high cellularity，nuclear atypia, cellular 
pleomorphism and brisk mitotic activity (Figure Llb). Microvascular 
proliferation and necrosis may also be seen (Kleihues, Burger & Scheithauer, 
1993). The mean age of those patients is about 49 years and they also show a 
slight male predominance (Reifenberger et al., 1997). 
Oligoastrocytomas 
Jn addition to monotypic gliomas, there are neoplasms which exhibit a 
mixture of two or more neoplastic glial cell types. By far, the most common 
7 
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Figure 1.1. H & E staining of oligodendrogliomas. (A) Grade H oligodendroglioma 
shows a clear halo of cytoplasm surrounding the round nuclei. (B) Grade 
ni oligodendroglioma displays a higher cellularity and mitosis ( indicated 
by arrows) is commonly observed (200X). 
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mixed gliomas are the oligoastrocytomas (Reifenberger et al., 1997). They 
are tumors with a conspicuous mixture of neoplastic oligodendrocytes and 
astrocytes, either diffusely intermingled or separated into distinct areas (Hart, 
Petito & Earle，1974; Maintz et al., 1997). However, the diagnostic criteria of 
these tumors on the assessment of the fractions of the two components are 
controversial, and values range from at least 1% to approximately 50% as a 
minimum for the astroglial component have been suggested (Hart, Petito & 
Earle, 1974; M0rk et aL, 1986; Hurtt et al., 1992; Kim et al., 1996). 
Microscopically, oligoastrocytomas are moderately cellular with low 
mitotic activity (Figure L2). Microcalcification, as well as microcystic 
degeneration, may be present (Kleihues, Burger & Scheithauer，1993). 
Anaplastic oligoastrocytomas are those with histological evidence of 
anaplasia, in the form of increased cellularity, nuclear atypia and increased 
mitotic activity. Vascular proliferation and focal necrosis may be present 
(Kleihues, Burger & Scheithauer, 1993). 
1.2.2.2. Ependymal Tumors 
This group of neoplasms represents about 5% of intracranial gliomas 
(Russell & Rubinstein, 1989). They arise from the ependymal lining of the 
cerebral ventricles and from the remnants of the central canal of spinal cord. 
In contrast to astrocytomas and oligodendrogliomas, ependymal tumors are 
sharply demarcated. Patients with ependymal tumors have a prognosis of 
about 50% of 5-year survival (Stam, 1991). Ependymal tumors occur 
predominantly in children and young adults (< 40 years). The following 
entities can be delineated: 
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Figure I.2. H & E staining of oligoastrocytomas (lOOX). (A) The astrocytic and 
oligodendroglial components are diffusely intermingled (diffuse type). (B) 
The two components are separated into distinct areas, and clusters of 
astrocytes are seen. A=astrocyte; 0=oligodendrocyte. 
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Ependymomas 
They are the most common ependymal neoplasms that usually located 
intraventricularIy and often cause clinical symptoms by blocking 
cerebrospinal fluid pathways. Microscopically, ependymomas are moderately 
cellular and exhibit low mitotic activity (Figure I.3a). Perivascular 
pseudorosettes and ependymal rosettes are observed histologically (Kleihues, 
Burger & Schdthauer，1993). Occasional mitoses, nuclear atypia and even 
foci of necrosis may be seen, but are not necessarily indicative of malignancy 
(Rosenlum, Bibao & Ang, 1996). There are four subtypes of ependymomas, 
i.e., cellular ependymomas, papillary ependymomas, clear cell ependymomas 
and tanycytic ependymomas (Schiffer & Wiestler，1997). 
Anaplastic Ependymomas 
They are the ependymal tumors that show advanced anaplasia, 
including high cellularity, variable nuclear atypia, marked mitotic activity and 
often prominent vascular proliferation (Figure L3b). Progression of the 
tumors is identified by the loss of typical architectural features, e.g., 
perivascular pseudorosettes and true rosettes (Kleihues, Burger & Scheithauer， 
1993). 
Myxopapillary Ependymomas 
They are a variant of ependymomas that occurs exclusively in the 
region of the cauda equina and originate from the filum terminale. It is 
histologically characterized by cuboidal to elongated tumor cells. These cells 
radially arranged around blood vessels with extensive mucoid and^or hyaline 
degeneration (Kleihues, Burger & Scheithauer，1993). Myxopapillary 
* ependymomas are slowly growing tumors that have a favorable prognosis. 
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Figure I.3. H & E staining of ependymomas. (A) Grade II ependymoma 
(lOOX). (B) Anaplastic ependymoma shows higher cellularity 
and marked mitotic activity (indicated by arrows) (200X). 
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Subependymomas 
They are nodular tumors composed of nests of ependymal cells in a 
dense glial fibrillary matrix. Mitoses are absent or rare. Microcysts and 
calcifications are common features (Kleihues, Burger & Scheithauer，1993). 
The most frequent site is the fourth ventricle (50-60% of case), followed by 
the lateral ventricles (30-40%) (Schiffer & Wiestler，1997). The tumors are 
frequently incidental autopsy findings. They may obstruct CNS pathways and 
thereby cause increased intracranial pressure. 
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I.3. Tumor Suppressor Genes 
Cancer arises in human because of the progressive accumulation of 
genetic abnormalities, including the functional activation of oncogenes，and 
the loss or inactivation of tumor suppressor genes (Brugge et al., 1991; 
Levine, 1992). Overexpression, mutation or rearrangement of oncogenes 
result in a protein that promotes the growth of tumor cells, while tumor 
suppressor genes are usually inactivated by mutation or deletion. 
l3A.p53 
Among all the tumor suppressor genes identified so far, p53 has 
received most ofthe attention, because mutations in that gene contribute to the 
development of up to 50% of all human cancers. 
1,3.1.1. Historical Perspectives 
In 1979，p53 protein was discovered independently by David Lane of 
the University of Dundee in Scotland, and by Amold Levine of Princeton 
University. It was first identified as a cellular protein because it formed a 
tight complex with the SV40 large T antigen (Lane & Crawford, 1979; Linzer 
& Levine，1979). Later, it was shown that the ElB oncoprotein of adenovirus 
also binds p53 (Samow et al., 1982). The binding of two different oncogenic 
viral tumor proteins to this protein suggested that p53 was crucial to 
tumorigenesis. The p53 gene was isolated in 1982 (Matlashewski et al., 1984; 
Lamb & Crawford, 1986) but it was not until 1989 that Levine and Vogelstein 
separately discovered that p53 was a tumor killer. Wild-type p53 gene 
suppressed the tumorigenic potential when introduced back into a tumorigenic 
cell line deleted inp53 (Chen et aL, 1990). With this fmding, many biologists 
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turned their interests on this cell's defender gene. In 1993，p53 won the 
science world's Academy Award, earning “Molecule of the Year" honors 
from the journal Science, p53 has also been named the “guardian of the 
genome" by many researchers. 
/. 3.1.2. Structure of p53 Gene and Protein 
In human, XhtpSS gene, designated TP53, is localized on the short arm 
of chromosome 17 (17p) at band 13.1, approximately 15-20 centimorgans 
from the telomere. The p53 gene spans a DNA region of 20 kilobases (kb), 
consists of 11 exons and encodes a 2.9-kb mRNA. The first exon that 
contains 213 base pairs is non-coding, and is found 8-10 kb away from exons 
2-11 (Lamb & Crawford, 1986). The gene contains five highly conserved 
domains that lie within exons 5, 7 and 8: domain I，codons 13-19; II, codons 
117-142; III，codons 171-181; IV, codons 234-258; and V, codons 270-286 
(Soussi, Caron de Fromentel & May, 1990). The relatively complex structural 
organization of the p53 gene is quite similar among different species. This 
sequence conservation suggests that p53 plays a significant role in cellular 
physiology. 
The p53 gene encodes a 393-amino acid nuclear phosphoprotein, with 
a molecuar weight of 53 kilodalton (kd) (Figure L4). The protein can be 
divided into three functional domains (Figure 1.5): (1) an acidic, proline-rich 
amino-terminus containing the transcriptional activation region; (2) the central 
DNA-binding region has the highly conserved domains II-V, and contains 
most of the oncogenic p53 mutations; and (3) a region rich in basic amino 
acids at the carboxyl-terminus, containing numerous functional sites, 
including three nuclear localization signals, the oligomerization region, 
nonspecific DNA binding domains, the TATA binding protein interaction site, 
a heat shock protein-binding domain, and the phosphorylation sites for cdc2 
15 
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kinase, cdk2 kinase and casein kinase II (Vogelstein & Kinzler，1992; Prives 
& Manfredi，1993). The wild-type protein is found in the nucleus and is 
typically present as a homodimeric (Prives & Manfredi, 1993) or tetrameric 
complex (Stenger et al,, 1992). Wild-type p53 has a very short half-life in the 
cell, about 20-30 minutes. The mutant forms of the protein, in contrast, 
frequently have a much longer half-life, generally measured in hours, which 
results in an apparent elevation in p53 expression. 
L 3.1.3. Functions of Wild- Type p53 Protein 
As a tumor suppressor, p53 can repress abnormal cell proliferation and 
growth, p53 probably accomplishes the tasks through its participation in at 
least four critical cellular pathways (Louis, 1994) (Figure L6). In response to 
DNA damage, p53 helps to maintain genetic stability by initiating a transient 
G1 cell cycle arrest that allows time for repair of damaged DNA before entry 
into S phase. The length of growth arrest depends on cell type. Ifthe damage 
is severe, it induces apoptosis or programmed cell death, p53 can also induce 
cellular differentiation. Wild type p53 induces B cells to differentiate (Prives 
& Manfredi, 1993), and can activate the expression of the muscle creatine 
kinase gene, which is tumed on during muscle cell differentiation (Weintraub, 
Hauschka & Tapscott，1991). In addition to a role in G1 cell cycle arrest, p53 
also participates in a G2 cell cycle checkpoint. Growth of cultured normal 
mouse fibroblasts was arrested when these cells were exposed to inhibitors of 
spindle assembly. However, under the same condition, mouse fibroblasts that 
were deficient of p53 underwent multiple rounds of DNA synthesis without 
completing chromosome segregation (Cross et al., 1995). Therefore, at least 
in mouse, p53 participates in a spindle checkpoint. It is important to realize 
that defects in p53-dependent surveillance of the DNA (p53-dependent G1 
checkpoint) could be responsible for chromosomal aberrations while defects 











































































































































































lead to aneuploidy and polyploidy. 
The mechanism by which p53 controls cell growth is that it acts as a 
transcription factor or a protein that regulates transcription factors in a cell 
(Weintraub, Hauschka & Tapscott，1991; Levine, 1992). This protein 
complexes with itself or other proteins and could recognize specific DNA 
sequences in enhancer and/or promotor elements of a gene, p53 may 
positively or negatively regulate a gene. It represses promotors that regulate 
the interleukin-6 (Santhanam, Ray & Sehgal，1991)，c-fos, c-jun (Ginsberg et 
a/” 1991) and bcl-2 (Miyashita et al., 1994) genes, whereas it stimulates the 
transcription of the MDM2 (Otto & Deppert，1993; Wu et al., 1993), gadd45 
(Kastan et aL, 1990), waf/cipl or p21 (El-Deiry et al., 1993) and the 
retinoblastoma gene (Osifhin et al., 1994). Promotors of genes that are 
repressed by p53 lack p53-binding sites, so it interacts with other transcription 
factors to effect the transcription machinery. Conversely, all the positively-
regulated promotors contain p53-binding sites. 
(1) MDM2 It is an oncogene that contains a p53 responsive element 
in the first intron. The protein product of which is 
expected to promote entry of cells into S phase ofthe cell 
cycle. Transactivation of MDM2 gene by p53 lead to the 
expression of MDM2 protein, which forms a complex 
with p53 protein and inactivates its transactivation 
function (Momand et al., 1992; Oliner et aL, 1993)，thus 
providing an autoregulatory feedback loop. 
(2) gadd45 It is a gene that contains a p53 responsive element in the 
third intron. Its level of transcription increases in 
response to DNA damage (Fomace et al., 1989). 
Therefore, gadd45 may play a role in DNA repair. 
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(3) p21 The gene product exerts a growth suppressor activity on 
tumor cells by inhibiting cyclin-dependent pathways, 
particularly the cyclin-dependent kinase 4，thus blocking 
the cell division (El-Deiry et aL, 1993). 
(4) Rb p53 stimulates the expression of retinoblastoma gene and 
this may suggest that both tumor suppressor genes act 
synergistically to suppress the cell growth. 
Therefore, biochemically, p53 proteins could function as transcription 
factors or regulatory subunits of transactivators or could directly control the 
initiation ofDNA replication. 
I-3.L4. Regulation and Modulation of the Functions ofp53 
p53 is extensively post-translationally modified, mostly by 
phosphorylation. The serine/threonine phosphorylation sites are clustered into 
two distinct domains at the N- and C-termini of the protein. The 
phosphorylation sites in human have been identified at amino acids 9, 15, 20, 
33 or 37，315 and 392 (Meek, 1994). 
The DNA-dependent protein kinase (DNA-PK) at human amino acid 
residues 15 and 37 (Anderson, 1993; Gottlieb & Jackson, 1995)，is shown to 
be capable of phosphorylating the N-terminus in vitro (Figure L5) ofp53, and 
interestingly, this kinase is linked to DNA damage response. 
However, the focus of work on p53 phosphorylation is put on C-
terminal sites and the kinases involved. Negative regulation of the sequence 
specific DNA binding activity of p53 by its C-terminus was first reported by 
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Hupp et al. (1992). Human p53 serine 315 can be phosphorylated by cyclin-
dependent protein kinases (cdks) (Bischoff et al； 1990; Sturzbecher et aL, 
1990). Previous in vitro study has shown that p53 is efficiently and 
selectively phosphorylated by S and G2M Cdks, namely cyclin B/Cdc2 and 
cyclin A/Cdc2 (Figure L5) (Wang & Prives，1995). Besides，Deffie et al. 
(1995) has proposed that the regulation ofp53 activity by cyclin E，which is 
active primarily in late G1, may be important in ensuring a proper progression 
through the cell cycle. 
Another kinase family that phosphorylates the C-terminus of p53 is 
protein kinase C (PKC) (Baudier et al., 1992). Serine 378 is the main residue 
of PKC phosphorylation which can activate the sequence specific DNA 
binding by p53. Finally, casein kinase II (CKII) also phosphorylates the p53 
C-terminus and activates p53 sequence specific DNA binding (Hupp et al,, 
1992). The CKII site is located at amino acid 392 in human. 
Moreover, non-specific DNA binding to the C-terminus may also 
regulate the sequence specific DNA binding activity of p53 (Jayaraman & 
Prives, 1995). Through interaction with the C-terminus, short (up to 30 
nucleotides) single DNA strands can stimulate allosterically sequence specific 
DNA binding, and this may be a physiological mechanism for activating latent 
p53. 
In conclusion, the C-terminus probably maintains p53 in a state that is 
incompatible with specific DNA binding. This negative interaction may be 
destabilized by a variety of mechanisms, such as phosphorylation and 
interaction with single stranded DNA. 
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I.3.5. Mechanism of p53 Inactivation 
p53 can be inactivated at either the gene or the protein level, but in 
human tumors, gene inactivation appears to be the most common mechanism. 
According to Knudson's two-hit hypothesis oftumor suppressor gene, 
a point mutation in one copy of the normal gene is usually accompanied by the 
loss ofthe remaining allele (Figure L7). Mutations ofp53 may be missense 
(a nucleotide substitution leading to an amino acid change and a full-length, 
mutant protein) or nonsense (formation of a stop codon and production of a 
truncated or absent protein). Most of the mutations are found within the 
conserved regions, i.e., exons 5 to 8 of the p53 tumor suppressor gene. 
At the protein level, a single mutant p53 can complex with the wild 
type p53 and negate the function of the wild type protein. This phenomenon 
is known as "dominant-negative mutation" (Herskowitz, 1987; Milner & 
Medcalf，1991). Only one p53 mutation is necessary for the functional 
inactivation of both alleles, although loss ofthe second, wild type allele may 
fiirther contribute to oncogenesis. 
In addition, viral proteins can also bind to and inactivate p53. It has 
been demonstrated that SV40 large T antigen, adenovirus ElB protein, 
papillomavirus E6 protein, Hepatitis Bx antigen (HBxAg), Epstein-Barr 
nuclear antigen-5 (EBNA-5), and EBV immediate-early protein (BZLF) are 
capable of binding with p53. The formation of protein complexes can 
stabilize the p53 protein and the binding to papillomavirus E6 protein can lead 
to rapid degradation (Scheffiier et aI., 1990). Another way to inactivate p53 is 
via the binding with the MDM2 oncogene. It is a cellular protein of 90 kd 
with transforming properties. It forms complex with wild type and mutant 
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Figure I.7. Schematic diagram showing the most common means of p53 
inactivation in gliomas. One copy of the normal allele (green) of p53 is 
mutated (red) and subsequently a portion of chromosome 17p that bears 
the second gene copy is lost. Modified from Louis 1994. 
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domain ofp53, and then prevents p53 from initiating transcription (Oliner et 
a/.，1993). MDM2 amplification has been found in approximately one-third of 
human sarcomas (Oliner et aL, 1992), but not in those with p53 gene 
mutations (Leach et al., 1993). This implies that MDM2 amplification is an 
alternative inactivating mechanism to p53 mutation. Finally, sequestration of 
p53 in the cytoplasm may inactivate the protein by preventing it from reaching 
its nuclear site of action (Moll, Riou & Levine, 1992). 
I 3.1.6. p53 Mutations Profiles in Human Tumors 
Germline mutations in the p53 gene are responsible for the Li-
Fraumeni cancer syndrome, characterized by an elevated risk of early-onset 
breast cancer, childhood sarcomas, and other neoplasms (Srivastava et al, 
1990; Malkin et al” 1992). In these families, one mutant p53 allele is 
inherited, and there is a reduction to homozygosity in the second allele that 
enhances the probability of cancer. Those carriers have a 50% likelihood of 
developing cancer by the age of30, and the likelihood increases to nearly 90% 
by the age of65. Moreover, germline p53 mutations have also been noted in 
6% of children with second malignant neoplasms (Malkin et al., 1992), more 
than 1% of children with sarcomas (Toguchida et al., 1992), and infrequently 
among women with breast cancer (Borresen et al., 1992). 
In human cancers, the most common change of p53 is point mutations 
within the coding sequence of this gene, which gives rise to an altered protien. 
Approximately one half of adult cancers of the colon, stomach, lung, 
esophagus, breast, liver, brain, reticuloendothelial tissues, and hematopoietic 
tissues contain the mutant p53 gene (Hollstein et aL, 1991; Levine, Momand 
& Finlay，1991; Chang et al； 1993; Levine et aL, 1994; Soussi et al., 1994). 
The p53 gene mutations in human cancer spread over a large area ofthe open 
reading frame, but their locations are not random. In a survey ofp53 missense 
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mutations from 191 human cancers, all were localized between amino acid 
residues 120 and 290，a region which encompasses the highly evolutionary 
conserved exons 5 through 8 (Marshall, 1991). Although a large number of 
p53 mutations have been described, there are a few which occur at much 
higher frequencies than the others, including those at codons 175, 248，249, 
273 and 282. Mutations in these amino acid residues account for 40% ofthe 
total missense mutations documented in human primary cancers. The high 
frequency ofthese hot spot mutations occurs with respect to the tissue origin 
ofthe cancer. Figure 1.8 showed the comparison ofthe mutational spectra of 
p53 from different types ofhuman tumors. It is clear from such a comparison 
that the frequency of mutation at particular codons differs somewhat among 
tumor types. For example, although colon and brain tumors share mutations 
in the three most common codons (175，248 and 273), in colon cancer, codon 
175 is mutated most frequently, while in brain, it is codon 273. Similarly, 
codon 249 is commonly mutated in lung cancer, but not as often in brain or 
colon cancer (Bogler et al., 1995). 
In lung cancers, mutations in the p53 gene are involved in both 
transversions and transitions. In non-small cell lung cancer, G:C to T:A 
transversions are the most frequent substitutions. The G to T transversions 
usually result from the interaction with environmental carcinogens, e.g., 
benz(a)anthracene in cigarette smoke. In contrast,p55 mutations in colorectal 
or brain cancer are almost always transitions (with frequency of79% and 73% 
respectively) (Ohgaki et al., 1995). Most of these mutations occur at the CpG 
dinucleotide and more than half is at codons 175, 248 or 273. Transition 
mutations at CpG sites are most likely due to the deamination of 5， 
methylcytosine residues. Tissue-specific methylation of CpG residues in the 
p53 gene gives a much higher rate of mutation than nonmethylated cytosine. 
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Figure 1.8. Comparison of the mutational spectra ofp53 from different types 
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1.3.2. Novel Genes 
Loss of sequences from human chromosome 10q has been associated 
with the progression of many human cancers. Analysis of GBM, prostate 
I cancer, malignant melanoma and endometrial cancer with multiple markers on 
the long arm ofchromosome 10 has provided evidence oftwo distinct loci for 
putative tumor suppressor genes on 10q23-25 and 10q24-qter, respectively 
OIurbst et al” 1994; Gray et al” 1995; Peiffer et al., 1995; Rasheed et aL, 
1995; Albarosa et al； 1996). Recently, a candidate tumor suppressor gene for 
the proximal locus and another at distal 1 Oq, were isolated. 
L3.2.1. PTEN/MMAC1 
In 1997, two research teams independently cloned a putative tumor 
suppressor gene, which resides on chromosome 10 (Li et al., 1997; Steck et 
a/., 1997). This gene is called PTEN (for phosphatase and tensin homolog 
deleted on chromosome 10) by Li et al； and MMAC1 (for mutated in multiple 
advanced cancers 1) by Steck et al. PTEN/MMAC1 is localized to 
chromosome 10q23.3 and it may be involved in several kinds of cancers, 
including gliomas, prostate and breast cancers. Recent studies have shown 
that mutations on PTEN/MMAC1 are frequent in glioblastomas (25-44%) (Liu 
et al, 1997; Rasheed et al., 1997; Wang et al” 1997)，endometrial cancer (34-
50%) (Risinger et al” 1997; Tashiro et al； 1997) and prostate cancer (as high 
as 43%) (Caims et al.’ 1997; Suzuki et al； 1998). Germline mutations in 
PTEN/MMAC1 have been detected in two autosomal dominant disorders, 
Cowden disease (Liaw et cd； 1997), a syndrome that confers an elevated risk 
for tumors of the breast, thyroid, and skin, and Bannayan-Zonana syndrome 
(Marsh et aL, 1997), a condition characterized by macrocephaly, lipomas, 
intestinal hamartomatous polyps, vascular malformations, and some skin 
disorders. The detection of germline mutations in these diseases suggests that 
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PTEN/MMAC1 functions as a tumor suppressor and this gene may play a role 
in the proper development and formation ofcertain tissues. 
The PTEN/MMAC1 gene consists of 9 exons with a transcript size of 
about 5.5 kb and encodes for a peptide of403 amino acids (Figure L9). The 
protein product of PTEN/MMAC1 contains an amino terminal domain with 
extensive homology to tensin, a protein that interacts with actin filaments at 
focal adhesions，and to auxilin, a protein involved in synaptic vesicle 
transport, as well as a domain with perfect homology to protein tyrosine 
phosphatase (Li et al., 1997; Steck et al., 1997). Moreover, there is a high 
homology between the human, mouse and dog sequence (99.75% animo-acid 
sequence identity between human and mouse), indicating that PTEN/MMAC1 
may be a highly conserved gene whose regulation and activity may play 
important roles in cellular processes. 
PTEN/MMAC1 is a dual-specificity phosphatase and has the ability to 
dephosphorylate serine, threonine and tyrosine residues in vitro (Myers et al” 
1997). The phosphatase activity of PTEN/MMAC1 is necessary for it to 
function as a tumor suppressor, as most of its mutations from tumor samples 
or Bannayan-Zonana syndrome were predicted to disrupt the phosphatase 
domain of PTEN/MMAC1 (Myers et al., 1997). These results imply that the 
phosphatase activity may involve in the modulation of phosphate-mediated 
growth signaling, and thus a role in oncogenesis. Recently, preferential 
regions of PTEN/MMAC1 mutation are identified (Fumari et al., 1997). 
These mutation hotspots appear to be confined to the tensiny'auxilin region at 
codon 15, the phosphatase catalytic domain within exon 5 (amino acid residue 
86-165)，and a putative tyrosine phosphorylation site at codons 232-241. 
Although the actual functions of PTEN/MMAC1 are still not well 
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PTEN/MMAC1 is a protein phosphatase that exhibits functional and specific 
growth-suppressing activity. 
L3.2.2. DMBT1 
Shortly after the discovery of PTEN/MMAC1, another new candidate 
tumor suppressor gene located on the long arm of chromosome 10 was 
identified in the same year (Mollenhauer et al., 1997). By using 
representational difference analysis, the authors identified a homozygous 
deletion at chromosome 10q25.3-26.1 in a medulloblastoma cell line and 
subsequently isolated a gene, which was named DMBT1 (deleted in malignant 
brain tumors). Intragenic homozygous deletions of this gene were detected in 
medulloblastomas and GBM and a lack of transcripts was found in most of the 
brain tumor cell lines (4/5) studied. 
The deduced amino-acid sequence of the open reading frame comprises 
a protein of 1,785 amino acids corresponding to a hypothetical molecular 
weight of 196 kd. The sequence contains an N-terminal stretch of 25 
hydrophobic amino acids that potentially represents a leader peptide with a 
predicted cleavage site between Serl9 and Thr20. The major part of the 
deduced protein consists of eight tandem repeats of scavenger receptor 
cysteine-rich domains (SRCR domains, 109 amino acids each) that are 94-
99% identical. The SRCR domains are separated by stretches of 20-23 amino 
acid residues (SRCR interspersed domains, SID) that share high homology. A 
ninth SRCR domain with lower homology (67% identity on average) is 
separated from the other SRCR domains by a Threonine-rich (45%) residues 
region of 20 amino-acid residues and a CUB domain. A second CUB domain 
and a Zona Pellucide (ZP) domain (262 amino-acid residues) are located 
downstream of the ninth SRCR motif. The C-terminus contains 28 amino-
31 
acid residues and twelve potential N-glycosylation sites (Figure I.10). 
As the deduced protein contains SRCR domains as the predominant 
motif, this allows DMBT1 to be classified as a new member of the SRCR 
superfamily. 
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201 CSAAQPQSTL RPESWPVRIS PPVPTEG^^S SLALRLVNGG DRCRGRVEVL | 
251 YRGSWGTVCO DYWDTNDANV VCRQLGCCWA MSAPGNAQFG QGSGPIVLDD I 
301 S w S | ^ " ^ WSCPHNGWLT HNCCHSEDAG vTwApJsRP TPSPOTWPTS | 
351 HASTAGPETSS LALRLVNGGD RCQGRVEVLY RGSWGTVCDD SWDTSDANW | 
401 CRQLGCGWAT SAPGNARFGQ GSGPIVLODV RCSGYESYLW SCPHNGWLSH I 
451 NCQHSEDAGV 1 S ^ W S T PSPOTLPTIT S S ? f e ? E S SLALRLVNGG | 
501 DRCQGRVBVL YQGSWGTVCD DSWDTNDANV VCRQPGCGWA MSAPGNARFG | 
551 QGSGPIVLDD VRCSGHESYP WSCPHNGWLS HNCGHSEDAG V^I^V^SRP | 
S R C R S p ^ • 
601 TPSPDTHPTS HASTAGSESS LALRLVNGGD RCQGRVEVLY RGSWGTVCDD | 
S51 YWDTNDANW CRQLGCGWAM SAPGNARFGQ GSGPIVLODV RCSGHESYLW | 
701 SCPHNGWLSH NCGHHEDAGV ^c!,^SQPT PSPDTWPTSH^f^TA^ESSL | 
751 AIRLVNGGDR CQGRVEVLYR GSWGTVCDDY WDTNDANWC RQLGCGWATS | 
301^APGNARFGQG SGPIVLDDVR CSGHESYLWS CPHNGWLSHN CGHHEDAGVI | 
SID6 p>> SRCR7 r*- I 
351 CSASQSQPTP SPDTWPTSRA STAGSESTLA LRLVNGGDRC RGRVEVLYQG | 
901 SWGTVCDDYW DTNDANWCR QLGCGWAMSA PGNAQFGQGS GPIVLDDVRC | 
^ ^ ^ R O M ^ ^ ^ ^ PHNGWLSHNC GHHEDAGVI^^^JsQSTPR PDTWLTTNLP I 
1001 ALTVGSESSL ALRLVNGGDR CRGRVEVLYR GSWGTVCDDS WDTNDANWC | 
1051 RQLGCGWAMS APGNABFGQG SGPIVLDDVR CSC^SYLWS CPHKGWLTHN | 
TTT p ^ CUB1 ^ • 
1101 CGHHEDAGVI CSATQI^TT TDWWHPTTTT TAR^SNCGG FLFYASGTFS I 
1151 SPSYPAYYPN NAKCVWEIEV NSGYRINLGF SNLKLEAHlQ CSFDYVEIFD | 
1201 GSIQSSLLLG KIC^DTRQIF TSSYNRMTIH FRSDISFQNT G ^ S 5 ^ ^ P | 
1251 SDATLRLVNL @SSYGLCAGR VEIYHGGTWG TVCDDSWTIQ EA£WCRQLG | 
1301 CGRAVSALGN AYFGSGSGPI TLDDVECSGT ESTLWQCRNR GWFSHNCNHR | 
1351 EDAGVICSGN_HLSTPAPXia_lj_R^D^SC GGrLSQPSGD FSSPFYPGNY | 
1401 PNNAKCVWDI EVQNNYRVTV IFRDVQLEGG CNYDYIEVFD GPYRSSPLIA I 
M 5 1 RVCDGARGSF TSSSNFMSIR FISDHSITRR GFRAEYYSSP ^ S ^ N ^ ^ ^ L | 
1501 PNHMQASVSR SYLQSLGFSA SDLVISTWNG YYECRPQITP NLVIFTIPYS I 
1551 GCGTFKQAlg DTIDYSNFLT AAVSGGIIKR RTDLRIHVSC RMLQNTWVDT I 
1601 MYI.^TIHV -#<TIQVEEV QYGNFDV§I3 FYTSSSFLYP VTSRPYWDL I 
1S51 NQDLWQAE： LHSDAVlTLF VDTCVASPYS NDFTSLTYDL IBSGCVRDDT I 
1701 YGPYSSPSLR IARFRFRAFH FLNRFPSVVL R C _ C R A Y DPSSRCYRGC I 
1751 VLRSKR'DVGS YQEKVOVyLG PIQLQTPPRR .E.EEPR* I 
I 
FigureL10. Predicted amino acid sequence of DMBTL The potential hydrophobic leader 
peptide is underlined. Dashed lines mark stretches with no homology to known 
proteins and the dotted line marks the C-terminal region with homology to rat 
ebnerin. The beginnings of the particular subunits are indicated by arrows. TTT 
denotes the threonine rich region. The potential N-glycosylation sites are boxed. 
The details of SRCR, SHD, ZP and CUB domains are discussed in text. From 
Mollenhauer et al., 1997. 
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I.4. Cytogenetic and Molecular Genetic Studies 
in Gliomas 
Li recent years, there have been great advances in the understanding of 
the genetic events that are involved in the pathogenesis and malignant 
progression of human gliomas, especially those of astrocytic gliomas. Two 
types of genes have been identified which are the targets for the genetic 
lesions. They are the dominantly acting oncogenes and the recessive tumor 
suppressor genes. 
1.4.1. Astrocytic Gliomas 
Cytogenetic analysis in human gliomas, including diffuse 
astrocytomas, oligodendroglial tumors and ependymal tumors have shown 
mixed results (Griffin et al., 1992; Ransom et al； 1992b; Thiel et aL, 1992; 
Debiec-Rychter et al,, 1995; Rosso et al., 1997). However, it is a common 
finding that the majority of low-grade gliomas are characterized by a normal 
karyotype or simple numerical changes. In contrast, some anaplastic 
astrocytomas and most glioblastomas displayed highly complex karyotypes, 
with numerous structural and numerical aberrations, the presence of double 
minutes (dmin), as well as differences in a ploidy level. The most common 
numerical chromosome aberrations found in gliomas were +7, -9，-10，-13,-
14，-17, +19，-22 and -Y (Ransom et al., 1992b; Debiec-Rychter et al； 1995). 
Structural changes involved predominantly the following chromosome arms: 
lq, 2q, 6q, 7q, 9p, 14q, 17p and 18p (Debiec-Rychter et al； 1995). It is 
believed that genes that are located at those sites may play a role in the 
tumorigenesis of gliomas. Some of them are discussed in detail below. 
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Tumor Suppressor Genes 
p53 
Allelic loss of chromosome 17p and p53 mutation are observed in 
approximately one-third of all three grades of adult astrocytomas (El-Azouzi 
et al., 1989; Chung et aL, 1991; Frankel et al., 1992; Fults et al.’ 1992; von 
Deimling et al” 1992a; Wu, Zhen & Darras，1993; Koga et al., 1994; Kraus et 
a/., 1994; Lang et al,, 1994; Rasheed et al., 1994; Sarkar et al, 1994; Tenan et 
al, 1994; van Meyel et al； 1994)，suggesting that inactivation of p53 is 
important in the formation of astrocytic tumors. Several studies have shown 
that p53 mutation represents an early genetic event in a subset of astrocytomas 
(Fults et al,’ 1992; Sidransky et al., 1992; von Deimling et al., 1992a; Van 
Meir et al., 1994). p53 mutations are rare in primary glioblastomas (10%) 
while secondary glioblastomas contain a high incidence of p53 mutations 
(>65%). Therefore, p53 appears to play a role both in the formation of low-
grade disease and in progression towards (the secondary) glioblastoma. 
PTEN/MMAC1 
Previous studies have shown that loss of heterozygosity (LOH) on 
chromosome 10 is observed in more than 60% of glioblastomas, but it is 
relatively rare in lower grades of astrocytic tumors (James et al., 1988; Bigner 
& Vogelstein, 1990; Ye, Wu & Darras，1993; Ohgaki et al., 1995). Therefore, 
it is considered that loss of chromosome 10 is a late event during astrocytoma 
progression. As discussed in 1.3.2.1.，PTEN/MMAC1 is a recently identified 
tumor suppressor gene localized to chromosome 10q23.3. It was found to be 
mutated in 30% of glioblastoma cell lines and xenografts, and 17-23% in 
primary glioblastomas (Li et al., 1997; Steck et al., 1997). Screening of 
PTEN/MMAC1 mutations in gliomas has revealed that this gene is mutated in 
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anaplastic astrocytomas (23%) (Rasheed et aL, 1997) and glioblastomas (25-
44%) (Liu et al” 1997; Rasheed et aL, 1997; Wang et al., 1997; Bostrom et 
a l , 1998), but not in low-grade gliomas and childhood gliomas of all grades 
(Rasheed et aL, 1997). 
DMBT1 
It is the new candidate tumor suppressor gene on the telomeric region 
of chromsome lOq，and it is found to be deleted in malignant brain tumors 
(Mollenhauer et al, 1997). Allelic losses at the DMBT1 locus were found in 
25% of medulloblastomas and 59% of GBM primary tumors, but not in the ten 
lower-grade astrocytomas studied (Mollenhauer et al., 1997). Homozygous 
deletions in DMBT1 were found in medulloblastomas and GBM (22%), but 
not in 33 normal subjects or in 28 other tumors of the nervous system, 
including meningioma, ependymoma and neuroblastoma (Mollenhauer et aL, 
1997; Bostrom et al., 1998). Moreover, lack of DMBT1 expression was 
confirmed in 4/5 (cell lines P4, U343-MG, D283Med and U138-MG) ofthe 
brain-tumor cell lines investigated (Mollenhauer et al., 1997). Further studies 
are required to characterize the role of this gene in the tumorigenesis of brain 
tumors. 
Chromosome 19q 
A putative tumor suppressor gene residing on the long arm of 
chromosome 19 is suggested to be involved in the pathogenesis of astrocytic 
gliomas. LOH on chromosome 19q occurs in 44% anaplastic astrocytomas 
and 24% of glioblastomas (von Deimling et al, 1992c; 1994a; 1994b). 
Deletion mapping has narrowed the candidate region to the 19ql3.3, between 
the markers D19S412 and STD loci (Rosenberg et a!., 1996). However, this 
gene has not been isolated yet. 
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Chromosome 22q 
The neurofibromatosis type 2 {NF2) gene is localized on the long arm 
of chromosome 22. As 20-30% of gliomas of all grades have shown LOH on 
chromosome 22q (James et al., 1988; Fults et al., 1992)，it was once suspected 
that this gene might play a role in the early stage of gliomagenesis. However, 
sequence analysis ofNF2 gene in astrocytoma of various grades revealed no 
mutations (Rubio et al., 1994). Moreover, other cytogenetic and LOH studies 
have shown 22q loss to the regions telomeric to NF2 (Ransom et al,, 1992a). 
Therefore, it is believed that another gene on chromosome 22q may be 
responsible instead, but this potential gene remains undefined. 
Oncogenes 
Gene amplification occurs in 45-50% of malignant human 
gliomas, especially in glioblastomas. However, amplified genes are not 
detected in the benign form of astrocytomas. Many genes have been shown to 
be amplified in gliomas, including EGFR, CDK4, SAS, MDM2, GLI, 
PDGFAR, MYC, N-MYC, MYCL1, MET, GADD153 and KIT (Bigner et al., 
1988; Collins, 1995). The most commonly amplified genes in glioblastomas 
is EGFR (Fuller & Bigner, 1992). Besides, amplifications of CDK4 and 
MDM2 genes have been shown to occur in nearly 15% of malignant gliomas 
(Reifenberger G et al, 1994). 
Epidermal growth factor receptor (EGFR) 
The EGFR gene maps to chromosome 7pll-12. It is a 
transmembrane receptor responsible for sensing its extracellular ligands, EGF 
and transforming growth factor beta (TGF-p), and for transducing this signal 
to cell. Amplification of EGFR is found in about half of glioblastomas but 
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less than 10% in astrocytomas and anaplastic astrocytomas (Wong et al., 
1987; Chaffanet et al, 1992; Schwechheimer, Huang & Cavenee，1995). 
EGFR overexpression is prevalent in primary glioblastomas (>60%). As most 
of the primary glioblastomas carry no p53 mutations, this indicates that 
overexpression of EGFR and mutations of the p53 gene are mutually 
exclusive events (Watanabe et aL, 1996). Besides, it is found that all 
glioblastomas with EGFR amplification show simultaneous loss of 
chromosome 10 (von Deimling et al., 1992b). 
MDM2 
The MDM2 gene lies in the 12ql4.3-ql5 chromosomal region. The 
gene product ofMDM2 contains a p53 DNA-binding site and is able to form a 
complex with the p53 protein, thereby abolishing the transcriptional activity of 
p53 (Momand et al.，1992). Thus, amplification or overexpression ofMDM2 
is an alternative mechanism to escape from p53-regulated control of cell 
growth. Amplification and overexpression ofMDM2 is observed in 8-10% of 
glioblastomas and anaplastic astrocytomas (Reifenberger et al., 1993). All of 
those glioblastomas are primary glioblastomas without p53 mutations (Biemat 
et al., 1997) Therefore, amplification and overexpression ofMDM2 may be a 
genetic hallmark of the primary glioblastoma which typically lacks a p53 
mutation. 
pl6/pl5, CDK4/CDK6, andRB 
The genes encoding pl6 and pl5, CDKN2A and CDKN2B, 
respectively, are mapped to chromosome 9p21, where interstitial and 
homozygous deletions are found in 44% of anaplastic astrocytomas, 63% of 
glioblastomas and in two-thirds of glioma cell lines (James et al., 1991; 
Olopade et aL, 1992; Ohgaki et aL, 1995). Their protein products act as 
inhibitors of cyclin-dependent kinases, especially CDK4 (12ql3-14) and 
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CDK6 (7q21-22), which are able to phosphorylate RB protein in conjunction 
with cyclin D (Serrano, Hannon & Beach，1993). CDK4 gene amplification 
was found in 27% of anaplastic astrocytomas and 76% of glioblastomas 
(Ohgaki et al” 1995). It is also found that pl6/pl5 deletion, CDK4/CDK6 
amplification and loss ofRB expression tended to be mutually exclusive. 
I.4.2. Non-Astrocytic Gliomas 
1.4,2.1. Ol igodendrogl ial Tumors 
Cytogenetics analysis on oligodendroglial tumors have been limited 
and have shown normal or non-clonal karyotypes in most cases (Rey et al., 
1987; Jenkins et al., 1989; Griffin et al” 1992; Ransom et al., 1992b; Thiel et 
al.，1992; Debiec-Rychter et al., 1995). However, a minor subset of tumors 
demonstrated simple clonal abnormalities. The most frequently observed 
numerical aberrations are loss of one sex chromosome, loss of chromosome 22 
and gain of chromosome 7. The common structural abnormalities have been 
reported on chromosome lp, 9p and 19q. Moreover, double minute 
chromosomes, that are cytogenetic hallmarks of gene amplification, have been 
observed in single cases of anaplastic oligodendrogliomas (Thiel et al., 1992). 
Molecular genetics analysis has shown chromosome 19 and 
chromosome 1 to be the most frequent genetic alterations found in 
oligodendroglial tumors. 
Tumor Suppressor Genes 
Chromosome 19 
As determined by loss of heterozygosity (LOH) analysis, LOH on 
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chromosome 19q is the most consistently reported genetic alteration in 
oligodendroglial tumors. However, the incidence ofLOH 19q varies between 
different studies, ranging from 23% to 86% in oligodendrogliomas (Bello et 
al” 1994; Reifenberger et al, 1994; Kraus et al, 1995; Ritland, Ganju & 
Jenkins，1995; Zhu et al., 1998), as high as 100% in anaplastic 
oligodendrogliomas (von Deimling et al., 1992c; Zhu et al., 1998) and about 
30-50% in oligoastrocytomas (Reifenberger J et al., 1994; Kraus et aL, 1995; 
Maintz et al., 1997). The losses involve all informative loci on 19q in the 
majority of oligodendrogliomas, suggesting that all, or almost all, of the 
chromosome arm had been deleted. It is believed that a putative tumor 
suppressor gene may reside on 19ql3.2-ql3.4 (von Deimling et al., 1994a; 
1994b; Yong et al., 1995). Recently, deletion mapping has refined a minimal 
region of approximately 900kb, at bands 19ql3.3, between markers D19S412 
and STD (Rosenberg et aL, 1996). 
Chromosome 1 
LOH of chromosome lp is the second most frequent genetic alteration 
in oligodendroglial tumors. The LOH frequency varies among different 
studies, ranging from 31-100% (Bello et al,, 1994; Reifenberger J et a/” 1994; 
Kraus et al” 1995; Zhu et cd., 1998). The precise location of the suspected 
tumor suppressor gene on lp is still poorly defined but has been suggested to 
be located at lp36-p32 (Bello et al.，1994). Recently, they showed evidence 
for two distinct candidate regions, one located distally at lp36, the other 
closer to the centromere, at lp35-p36 (Bello et aL, 1995). 
Moreover, it is also found that all oligodendrogliomas with LOH on lp 
also have lost alleles on 19q，but some exhibit LOH 19q without LOH lp 
(Reifenberger J et al., 1994; Bello et al； 1995; Kraus et al； 1995). Thus, 
LOH lp and LOH 19q represent sequential events in which LOH 19q may 
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precede LOH lp. Alternatively, inactivation of one of these genes may 
promote alterations in the other gene. 
Therefore, high incidence of LOH on chromosome 19q and lp in 
oligodendrogliomas and oligoastrocytomas suggests that putative tumor 
suppressor genes residing in those regions may be involved in the formation 
ofgliomas with oligodendroglial features. 
p53 
In contrast to astrocytic gliomas, studies on oligodendroglial tumors are 
relatively limited. Previous studies have shown a high percentage of p53 
expression in oligodendrogliomas and oligoastrocytomas (Kros et al., 1993; 
Pavelic et al., 1994; Hagel et al., 1996; Beckmann & Prayson, 1997). Only 
very few molecular analyses have been done on LOH on V7p/p53 mutations, 
and in most of the studies, the sample sizes were smaller than 10 (Table L3). 
Four larger studies (Ohgaki et al., 1991; Hagel et aL, 1996; Maintz et cd,, 
1997; Zhu et al； 1998) have shown LOH 17p occurred at a frequency of 12% 
in oligodendrogliomas, 38-40% in anaplastic oligodendrogliomas, 20% in 
oligoastrocytomas and 35% in anaplastic oligoastrocytomas. For mutational 
analysis ofp53, the frequencies ranged from 5-14% in oligodendrogliomas, 0-
21% in anaplastic oligodendrogliomas, 29% in oligoastrocytomas and 35% in 
anaplastic oligoastrocytomas. It is found that the results varied among 
different studies and the status of p53 in oligoastrocytomas is still not well-
defined. 
Interestingly, those oligoastrocytomas with p53 mutations md/or 17p 
loss do not have LOH on lp and 19q, and vice versa (Reifenberger J et al., 
1994; Maintz et al., 1997). Moreover, in a study of 38 oligoastrocytomas, 
those oligoastrocytomas with lp (52%) and 19q (70%) loss were more often 
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Table I.3. Molecular studies of p53 or chromosome 17 on oligodendroglial 
and ependymal tumors. 
Authors Methods Used ‘ Results ^  
Ohgaki et al., 1991 PCR-SSCP, direct sequencing 2/17 0 ; 0/15 E with 
mutations 
Wu JK et al., 1993 PCR-SSCP, direct sequencing 0/2 0 ; 0/8 E with no 
mutations 
Ng et al., 1994 PCR-SSCP, direct sequencing 0/10 0 ; 0/8 E with no 
mutations 
Rasheed et al., RFLP-LOH 17p 1/8 0 ; 0/2 AO; 1/8 E 
1994 with LOH 
PCR-SSCP, direct sequencing 1/9 0 ; 0/2 AO; 0/11 E 
with mutations 
Bijlsma et al., 1995 STR-LOH 17p 2/17 E with LOH 
Lee et al., 1995 RFLP-LOH 17p 0/4 0 ; 2/3 AO; 0/2 E 
with LOH 
PCR-SSCP, direct sequencing 0/6 0 ; 1/3 AO; 0/3 E 
with mutations 
Tominaga et al., PCR-SSCP, direct sequencing 1/5 AE with mutations 
1995 
Fink et al., 1996 PCR-SSCP, direct sequencing 0/31 E with mutations 
Hagel et al., 1996 PCR-SSCP, direct sequencing 6/44 0 ; 4/19 AO with 
mutations 
Reifenberger et al., PCR-SSCP, direct sequencing 1/7 0 ; 1/2 OA with 
1996b mutations 
von Haken et al.， RFLP-LOH 17p 9/18 pediatric E with 
1996 LOH 
PCR-SSCP, direct sequencing 1/18 pediatric E with 
mutations 
Weber et al., 1996 PCR-SSCP, direct sequencing 1/5 0 with mutations 
Maintz et al., 1997 STR-LOH 17p 2/17 0 ; 0/6 AO; 5/20 
OA; 6/17 AOA with 
LOH 
PCR-SSCP, direct sequencing 1/19 0 ; 0/6 AO; 6/21 
OA; 6/17AOA with 
mutations 
Zhu et al., 1998 STR-LOH 17p 38-40% AO with LOH 
^PCR-SSCP: polymerase chain reaction-single-strand conformation polymorphism analysis; 
RFLP: restriction fragment length polymorphism analysis; STR: short tandem repeat, 
usually di-, tri- and tetranucleotide (CA)n repeats; LOH: loss ofheterozygosity. 
0 : oligodendroglioma; AO: anaplastic oligdendroglioma; OA: oligoastrocytoma; AOA: 
anaplastic oligoastrocytoma; E: ependymoma; AE: anaplastic ependymoma. 
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oligodendroglioma-predominant, whereas those with p53 mutations (32%) 
were more often astrocytoma-predominant (Maintz et al” 1997). These data 
suggest that oligoastrocytomas are genetically heterogeneous. One subset is 
genetically related to astrocytomas while the other is genetically related to 
oligodendrogliomas. 
Chromosome 10 
Malignant progression of oligodendroglial tumors usually involves 
deletions on chromosome 10 (Reifenberger J et al., 1994). LOH of 
chromosome 10 was occasionally detected in oligodendroglial tumors, 
especially in malignant gliomas (Table L4). One larger study on anaplastic 
gliomas has reported that allelic deletions on chromosome 10 were observed 
in 15% (2/13) of anaplastic oligodendrogliomas and 25% (2/8) anaplastic 
oligoastrocytomas. The allelic loss of one anaplastic oligoastrocytoma was 
confined to 10q distal to the D10S22 locus (10q21.1-qter) (Reifenberger J et 
al, 1994). The recently cloned PTEN/MMAC1 tumor suppressor gene is a 
target gene in anaplastic oligodendroglial tumors with 10q loss. One previous 
study has shown no PTEN/MMAC1 mutations in 14 grade II/III 
oligodendrogliomas examined (Rasheed et al., 1997), but recently, 2 out o f22 
oligodendrogliomas showed PTEN/MMAC1 mutations at exons 2 and 4 
respectively, but not found in 37 oligoastrocytomas studied (Duerr et cd., 
1998). 
Another common deletion region in gliomas is at chromosome 10q25-
q26 (Rasheed et al； 1995; Maier et aI., 1997). Jn both studies, 21 out o f a 
total of 179 gliomas, including 5 grade II/III astrocytomas, 14 GBM and 2 
grade II oligodendrogliomas, showed partial deletions on chromosome lOq. 
The combined data suggest that the minimal deletion region is in 10q25.1, 
with a distance of 5 cM, between markers D10S587 and D10S216. 
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Table L4. Molecular studies ofPTEN/MMACl or chromosome 10 on 
oligodendroglial and ependymal tumors. 
Authors Methods Used ‘ Results ^  
Ransom et al , RFLP-LOH 10 1/18 0 ; 1/13 E with LOH 
1992a 
Ransom et al, RFLP -LOH 10 1/7 AOA with LOH 
1992b 
Rasheed et al., 1992 RFLP-LOH 10 1/2 0 with LOH 
Karlbom et al., RFLP-LOH 10 0/4 0 ; 2/2 AO; 0/3 OA; 0/1 
1993 AOA; 1/1 AE with LOH 
Ye Z et al., 1993 RFLP-LOH 10 1/1 AOA; 0/3 E with LOH 
Rasheed et al.， RFLP-LOH 10 1/9 0 ; 0/2 AO; 2/10 E with 
1994 LOH 
Reifenberger et al.，RFLP-LOH 10 4/21 AO+AOA with LOH 
1994 
Bijlsma et al., 1995 STR-LOH 10 2/17 E with LOH 
Lee et al., 1995 RFLP-LOH 10 0/4 0; 0/3 AO; 0/2 E showed 
no LOH 
Rasheed et al., 1995 STR-LOH 10 1/11 0 ; 1/12 E with LOH 
Albarosa et al., STR-LOH 10 22/91 anaplastic gliomas, 
1996 including 2 AO 
Sonoda et al., 1996 STR-LOH 10 1/3 AE with LOH 
Maier et al., 1997 STR-LOH 10 2/4 0 ; 2/2 AOA with LOH 
Rasheed et al., 1997 PCR-SSCP, direct 0/9 0 ; 0/5 AO with no 
sequencing mutations 
Duerr et al., 1998 PCR-SSCP, direct 2/22 0 ; 0/37 OA; 0/15 E 
sequencing with mutations 
apCR-SSCP: polymerase chain reaction-single-strand conformation polymorphism analysis; 
RFLP: restriction fragment length polymorphism analysis; STR: short tandem repeat, 
usually di-, tri- and tetranucleotide (CA)n repeats; LOH: loss ofheterozygosity. 
0 : oligodendroglioma; AO: anaplastic oligdendroglioma; OA: oligoastrocytoma; AOA: 
anaplastic oligoastrocytoma; E: ependymoma; AE: anaplastic ependymoma. 
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Chromosome 9 
Allelic loss on chromosome 9p was exclusively found in anaplastic 
oligodendroglial tumors, which accounted for about 33% (7/21) of cases 
(Reifenberger J et al； 1994). It is possible that the CDKN2A gene on 9p21 
may represent the critical target of the 9p deletions in anaplastic tumors. 
However, recent study has shown that no homozygous deletion or mutations 
of CDKN2A were observed in a series of nine anaplastic oligodendrogliomas 
(Sato etal” 1996). 
Moreover, genetic alterations of other cell cycle regulatory genes, such 
aspl5, CDK4, cyclin D1, appear to be rare in oligodendroglial tumors (Sato et 
aL, 1996). 
Others 
In addition to specific chromosomal losses, regions on chromosomes 4, 
6 and 11 were found to be lost in 30-80% of both oligodendrogliomas and 
anaplastic oligodendrogliomas (Zhu et al.’ 1998). This recent study has also 
shown high LOH frequency on chromosomes 6 and 11 in addition to that 
identified previously on chromosomes 1，19 and 4. This suggests that 
multiple candidate tumor suppressor genes on these chromosomes may 
underlie the processes of initiation andAn* progression of oligodendroglial 
tumors. 
Oncogenes 
About half of both low- and high-grade oligodendrogliomas show 
strong expression of EGFR mRNA and protein. EGFR gene amplification 
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was uncommon and only occasionally found in anaplastic oligodendroglioma 
and anaplastic oligoastrocytoma (Reifenberger J et al., 1994; Reifenberger et 
a/.，1996a). The molecular mechanism responsible for the increased 
transcription of EGFR in these tumors remains unknown. 
In additions to EGFR, MDM2 has only been rarely studied in 
oligodendrogliomas. Previous studies have not shown any MDM2 
amplification in a total of 19 grade M I I oligodendrogliomas (Reifenberger et 
al., 1993;Huntere^a/., 1995). 
1.4.2.2. Ependymal Tumors 
Karyotypic and cytogenetic analyses of ependymomas have lagged far 
behind studies done in astrocytic tumors. These studies on ependymal tumors 
have often shown complex cytogenetic abnormalities. About 30% of 
ependymomas show abnormalities involving chromosome 22, primarily 
monosomy (Rey et al； 1987; Jenkins et al； 1989; Stratton et al； 1989; 
Ransom et al., 1992a; Thiel et al., 1992; Weremowicz et al； 1992; Neumann 
et al., 1993; Sawyer et al” 1994; Bijlsma et al., 1995; Slavc et aI., 1995; 
Wernicke et al, 1995). Abnormalities involving 9p, 10，17 and 13 are less 
common in ependymomas than in high-grade astrocytomas. Moreover, 
chromosomes 6q and l lq may harbor factors that are important in the 
oncogenesis of ependymomas. It is because monosomy 6 (Jenkins et al., 
1989; Amoldus et al.’ 1992; Griffin et al., 1992; Neumann et al., 1993; 
Wernicke et aL, 1995) and monosomy 11 (Jenkins et aL, 1989; Amoldus et 
al, 1992; Ransom et al” 1992a; Weremowicz et al., 1992; Sawyer et al., 
1994; Wernicke et al., 1995) have been reported. Besides, rearrangement 
involving l lq l3 (Sainati et aL, 1992; Neumann et al., 1993) and deletions on 
6q were occasionally observed CNeumann et al., 1993; Rogatto et al., 1993). 
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Tumor Suppressor Genes 
Chromosome 22q 
Molecular genetic studies are relatively rare compared with those of 
astrocytic tumors. The available data suggest that chromosome 22q may 
harbor a tumor suppressor gene important in the formation of ependymomas 
as allelic loss on chromosome arm 22q was frequently detected (Bijlsma et al.， 
1995). As Neurofibromatosis Type 2 patients have an increased susceptibility 
to ependymomas, the neurofibromatosis 2 {NF2) gene, which resides on 
chromosome 22q, is the target of investigation. However, some investigators 
have showedM^2 mutations in ependymomas (Birch et aL, 1996) while others 
have been unable to detect any mutations in a significant fraction of 
ependymomas (Rubio et al., 1994; von Haken et al., 1996). These results may 
suggest that NF2 gene is important in the formation of some ependymomas, 
but another, yet unidentified, tumor suppressor gene on chromosome 22q, may 
be critical in the tumorigenesis of certain ependymomas. 
p53 
p53 mutations are common in astrocytic tumors, but its role in 
ependymal tumors is not well-characterized. Previous studies have shown 
allelic loss on chromosome 17p in 2/17 ependymomas (Bijlsma et al； 
1995) and 9/18 pediatric ependymomas (von Haken et aL, 1996) (Table 
I.3). No p53 mutations were detected in a total of 46 ependymomas 
analysed (Ohgaki et aL’ 1991; Fink et al., 1996). Nevertheless, in a study 
of 5 anaplastic ependymomas, 1 p53 mutation was found in exon 5 
(Tominaga et al., 1995). Moreover, in pediatric ependymomas, 1 germline 
p53 mutation was detected out o f l 8 cases (von Haken et al； 1996) (Table 




Molecular genetic studies on chromosome 10 are only rarely studied. 
Previous study has shown LOH on chromosome 10 in 8 grade M I I 
ependymomas over a number of studies (Table L4). As PTEN/MMAC1 is 
a potential tumor suppressor gene on chromosome lOq, its status in 
ependymomas has recently been examined. PTEN/MMAC1 gene 
mutations were not found in 15 ependymomas (Duerr et al., 1998). 
Oncogenes 
Gains of chromosome 7, monosomy 9 and monosomy 13 are 
occasionally detected in ependymomas (Griffin et al., 1992; Sawyer et al,, 
1994; Wemicke et al., 1995). However, no EGFR gene amplification has 
been observed so far (Bijlsma et al., 1995), and mutations or deletions of 
pI5/pl6, or amplification of CDK4 are also failed to be detected (Sato et 
a/.，1996). Moreover, previous studies on 10 grade II/III ependymomas 
did not find any MDM2 amplification (Reifenberger et aL, 1993; Hunter et 
al., 1995). 
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The molecular gerietics of astrocytic tumors have been extensively studied 
in recent years, and the rapid advances in the understanding of their molecular 
genetics may provide a basis for classification and prognostication (von 
Deimling et al., 1992b; Kleihues et al, 1997a; 1997b; Louis, 1997). However, 
the molecular genetics of non-astrocytic gliomas have been studied to a much 
lesser extent. Oligodendrogliomas and ependymomas are non-astrocytic gliomas 
that account for 5-15% of intracranial gliomas. Previous cytogenetic and 
molecular genetic studies have revealed consistent and high frequency of allelic 
loss on chromosome 19q and lp36-32 in oligodendrogliomas. Abnormalities of 
chromosome 22 are the most common genetic alterations found in 
ependymomas. Besides, abnormalities involving 9p, 10，17 and 13 are also 
occasionally found in both types of non-astrocytic gliomas (as described in 1.4.2). 
p53 alterations represent 50% of all human cancers, including gliomas. It 
is well documented that allelic loss of chromosome 17p and p53 mutation are 
observed in about one-third of all grades of diffuse astrocytomas (Bogler et al., 
1995). Therefore, inactivation of p53 is important, and represents an early 
genetic event in the formation of astrocytic gliomas. However, molecular 
genetics studies on p53 in non-astrocytic gliomas remain limited, p53 protein 
expression is frequently observed in oligodendrogliomas and oligoastrocytomas 
(Kros et al, 1993; Pavelic et al., 1994; Hagel et al., 1996; Beckmann & Prayson, 
1997)，and allelic loss on 17p has also been reported in oligodendrogliomas and 
ependymomas (Bijlsma et al, 1995; Bogler et al； 1995; von Haken et al., 1996). 
Nevertheless, the number of cases with p53 mutational analysis remains small. 
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In addition to mutational inactivation, oncogene amplification is also 
found in many tumors. MDM2 is the second most frequently amplified gene in 
gliomas. Recent studies have described that MDM2 amplification occurs in 9% 
ofmalignant gliomas (Reifenberger et aL, 1993). The protein product o f M D M 2 
binds to p53 protein attd prevents p53 to function as a transcription factor 
(Momand et al” 1992; Oliner et al., 1992). Reifenberger et al (1993) also 
shown that tumors with MDM2 amplification contained no p53 mutation. 
Therefore, amplification of MDM2 may be an alternative molecular mechanism 
to allow malignant gliomas to escape from normal p53-regulated growth control. 
Loss ofchromosome 10 is associated with the malignant progression from 
low-grade glioma to G B M . L O H on chromosome 10 has been observed in about 
70% of glioblastomas (von Deimling, 1997). In oligodendroglial tumors, allelic 
loss on chromosome 10 is occasionally observed in their malignant form. 
Nevertheless, the number of cases studied was usually small. One larger group 
has shown L O H on chromosome 10 in 19% (4/21) anaplastic oligodendroglial 
tumors (Reifenberger et al., 1994). The long arm of chromosome 10 was 
indicated as the common deletion region. A recently identified tumor suppressor 
gene, PTEN/MMAC1, located on chromosome 10q23.3 is the target for 
mutational analysis. Recent studies have shown PTEN/MMAC1 mutations in 
23% of anaplastic astrocytomas (Rasheed et al., 1997) and 25-44% of 
glioblastomas (Liu et aL, 1997; Rasheed et aL, 1997; Wang et al,, 1997; Bostrom 
et al., 1998). As L O H on chromosome 10 is often associated with EGFR 
amplification, the identification of PTEN/MMAC1 as a dual-specificity 
phosphatase (Myers et al., 1997) may suggest a potential biochemical link 
between the roles of EGFR amplification and the loss of function of 
PTEN/MMAC1 in oncogenesis, as the EGF receptor acts via tyrosine phosphate-
mediated signal transduction. EGFR is often overexpressed in 
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oligodendrogliomas OR^ eifenberger et al., 1996a; 1996b) and abnormalities of 
chromosome 10 have also been demonstrated in both oligodendrogliomas and 
ependymomas. However, the status ofPTEN/MMACl in these neoplasms is not 
known. 
In addition to PTEN/MMAC1, another region on chromosome lOq, i.e., 
10q24-q26, has also shown to be commonly deleted in gliomas (Rasheed et al” 
1992). The deletion region is delineated to be at chromosome 10q25.1, between 
markers D10S587 and D10S216 (Rasheed et al., 1995). Recently, a novel tumor 
suppressor gene for brain tumors, located on chromosome 10q25.3-26.1 has been 
isolated and named as DMBT1 (Mollenhauer et al,, 1997). As two out of four 
low-grade oligodendrogliomas displayed partial deletion on 10q25-q26 (Maier et 
a/.，1997)，this common deletion region, as well as the site where DMBT1 
resided, become the target for investigation. 
Therefore, the objectives of this study are: 
^ to define the role of tumor suppressor genes, p53 and PTEN/MMAC1, in the 
development of the different types of oligodendroglial tumors, ependymomas 
and their malignant counterparts; 
务 to investigate the role of gene sites at 10q23 and 10q25-26 in the malignant 
transformation of oligodendroglial tumors. 
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• 瓜 MATERIALS AND MEmODMm 
Hi this study, non-astrocytic gliomas including oligodendrogliomas, 
oligoastrocytomas and ependymomas were subjected to L O H 10q analysis, p53 
and PTEN/MMAC1 mutational analyses and MDM2 gene amplification by 
differential PCR technique. 
III.1. Patients and Materials 
Oligodendroglial and ependymal tumors are uncommon central nervous 
system tumors and only archival paraffin-embedded materials were used in this 
study. Tumor samples were collected from (1) hospitals in Hong Kong, 
including Prince of Wales Hospital, Tuen Mun Hospital, Queen Elizabeth 
Hospital and Kwong Wah Hospital, (2) hospitals from China, Anhui Provincial 
Hospital and Beijing Hospital, and (3) Westmead Hospital in Australia. Blood 
samples from some of the patients were also collected and were stored at -70°C 
freezer until used. 
Tumor samples were reviewed and classified according to World Health 
Organization (WHO) criteria (Kleihues, Burger & Scheithauer，1993) (Table 
ni.l). The W H O grading is a malignancy scale ranging across a wide variety of 
intracranial neoplasms. It describes the histological evidence ofdifferentiation or 
anaplasia. The biological behavior of CNS tumors is characterized by a 
histological grade ranging from I (benign) to rV (malignant). 
52 
Table III.1. W H O classification of oligodendroglial and ependymal tumors. 
Tumors WHO Classification 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ " " " ^ ^ ^ ^ " " " ^ ^ " " • ^ ^ ^ " • " ^ ^ " * • ^ ^ ^ ^ ^ ^ " * ^ “ 
Oligodendroglial tumors 
Oligodendroglioma W H O grade II 
Oligoastrocytoma W H O grade II 
Anaplastic oligodendroglioma W H O grade III 
Anaplastic oligoastrocytoma W H O grade III 
Ependymal tumors 
Myxopapillary ependymoma W H O grade I 
Subependymoma W H O grade I 
Ependymoma W H O grade II 
Anaplastic ependymoma W H O grade III 
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Grading 
A total of 61 oligodendroglial and ependymal tumors were used in our 
study. For oligodendroglial tumors, 16 were grade II, 12 were grade III and 7 
were oligoastrocytomas (grade II). Patients with oligodendroglial tumors 
consisted ofl8 males and 10 females, and those with oligoastrocytomas consisted 
of 1 male and 6 females. There were 24 grade II and 2 grade III ependymal 
tumors. Those patients with ependymomas consisted oflO males and 16 females. 
Age 
The ages of patients with oligodendroglial tumors ranged from 13 to 79， 
with a median of43. For ependymal tumors, the ages ofpatients ranged from 1 
to 69，with a median of 26. 
The clinical features of the patients were presented in Table HL2 and 
Table IIL3. 
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Table III.2. Clinical features of patients with oligodendroglial tumors. 
Oligodendroglial Tumors  
Case No. Age Sex | Diagnosis ^ | SiteofTumors ^ 
Prince ofWales Hospital, Hong Kong  
0-PWl 23 I M 0 cerebellum 
Q-PW2 47 M ~ " 0 left frontal lobe 
Q-PW3 46 M 0 left frontal lobe 
0-PW4 70 F 一 AO corpus callosum 
0-PW5 ^ M 0 frontal lobe 
0-PW7 19 F 0 righttemporal lobe 
Q-PW8 52 M — 0 left frontal lobe 
0-PW9 30 M ~ 0 — rightfrontallobe 
Q-PW10 30 M d " cerebellum — 
Q-PW11 7 M — OA ‘ — right parietal lobe 
0-PW12 61 F ~ " AO bifrontal lobe 
0-PW13 20 F — 0 — temporal lobe 
0-PW14 57 F 一 OA ‘ right temporal lobe 
0-PW15 70 M 一 AO right hemisphere 
0-PW16 70 M AO left fronto-parietal lobe 
0-PW18 4 3 ~ F 一 QA^ cerebellum 
0-PW19 35 M _ 0 一 parietallobe 
O-PW20 ^ F AO left frontallobe — 
0-PW21 50 F 一 OA' corpus callosum 
0-PW23 60 M AO left frontal lobe 
0-PW24 - 29 — M 0 l^ft fronto-temporal lobe 
0-PW25 _ 40 — M 0 — frontal lobe 
0-PW26 _ 38 ~ M AO right frontal lobe 
0-PW27 — 59 M AO I^ft frontal lobe — 
0-PW28 58 M AO left frontal lobe 
Tuen Mun Hospital, Hong Kong  
0-PW17 I 40 I F I AO I right frontal lobe 
Queen Elizabeth Hospital, Hong Kong  
0-QEl 38 M 0 n.a. 
Q-QE2 — 5 5 F — OA: n.a. 
0-QE3 57 F ~ OA^ — n.a. 
0-QE4 43 F AO n.a. 
Kwong Wah Hospital, Hong Kong  
Q-KW1 I 13 F 0 leftoccipitallobe 
Q-KW2 I 18 F 0 left occipital lobe 
Anhui Provincial Hospital, Hefei, China  
0-AH208 I 29 | M | 0 | n.a. 
Beijing Hospital, Beijing, China  
0-BJ22 I 16 I F I OA^ | n.a. 
Westmead Hospital, Sydney, Australia  
Q-AU1 ^ F AO I corpus callosum 
a 0，oligodendroglioma; AO, anaplastic oligodendroglioma; OA', oligoastrocytoma, compact type; 
OA ,^ oligoastrocytoma, diffiise type. 
b n.a., not available. 
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Table III.3. Clinical features of patients with ependymal tumors. 
Ependymal Tumors  
Case No. Age Sex Diagnosis ^ SiteofTumors ^ 
Prince ofWales Hospital, Hong Kong  
E-PW2 I 25 [ M E IV ventricle 
E-PW3 27 M 一 E n.a. 
E-PW4 一 4 F — E — IV ventricle ‘ 
E-PW5 ^ M E rightthalamus 
E-PW6 ^ F E cauda equina 
E-PW7 69 _ F E n.a. 
E-PW8 ^ M E spinal cord 
E-PW10 ~ 3 8 ~ F 一 E cerebellum 
E-PW11 1 F E cerebrum 
E-PW12 7 F E IV ventricle — 
E-PW13 31 F — E cerebellum 
E-PW14 28 M 一 E spinal cord 
E-PW15 6 5 ~ F 一 E spinal cord 
E-PW17 ^ F E spinal cord “ 
E-PW18 ^2 M E cervical cord — 
E-PW19 — 22 F E posteriorfossa 一 
E-PW20 n M E cerebellum 一 
E-PW21 12 F - E — cerebellum 
E-PW22 40 M E spinal cord — 
E-PW23 4 5 ~ F - E spinal cord 
E-PW24 39 F 一 E 一 cauda equina 
E-PW25 8 F AE posterior fossa 
E-PW26 27 M — AE rightthalamus 
E-PW27 2 F 一 E - cerebrum 
E-PW28 12 F E posterior fossa 
Anhui Provincial Hospital, Hefei, China  
E-AH240 I 8 I M | E | n.a. 
a E, ependymoma; AE, anaplastic ependymoma. 
b n.a., not available. 
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III.2. Collection of Samples 
All of the tumor specimens were formalin-fixed and then embedded in 
paraffin. These paraffin blocks were stored at room temperature in the archival 
tissue bank. 
Blood samples (10 ml) were collected in 15 ml Falcon tubes, which 
contained 2 ml anticoagulant, A C D (citric acid; sodium citrate; glucose). They 
were then immediately stored at -70°C freezer. 
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III.3. DNA Extraction 
High molecular weight D N A was extracted from paraffin-embedded 
tissues and blood samples using conventional protocols (Maniatis, Fritsoh & 
Sambrook, 1989) and commercial D N A extraction kit. 
ni.3.1. Extraction of Genomic DNA from Formalin-fixed 
Paraffin-Embedded Tissues 
Genomic D N A from paraffin-embedded tumors was isolated by standard 
protocol of proteinase K digestion and phenol/chloroform extraction (Maniatis, 
Fritsoh & Sambrook，1989). In some cases, D N A was purified using the 
commercially available QIAamp Tissue Kit (Qiagen Inc., Hilden, Germany). The 
latter method generated better quality ofDNA and gave a more consistent yields. 
The protocol ofDNA extraction was described in detail below: 
Standard protocol 
Fifty microns of paraffin-embedded tissues were cut and placed into sterile 
1.5 ml tubes. Li order to remove the paraffin, 1.2 ml xylene was added and the 
tubes were incubated at 37°C for 30 minutes. The precipitates were spun down 
and xylene was discarded. 1.2 ml 100% ethanol was added into the tubes which 
were then incubated at room temperature for 10 minutes. This step was repeated 
once to remove residual xylene. After centrifugation, ethanol was removed and 
the precipitates containing tumor tissues were then dried under vacuum for 15 
minutes. 1 ml D N A extraction solution containing Saline Tris-EDTA (0.1 M 
NaCl, 0.05 M Tris, pH 7.5, 1 m M ethylenediamine tetraacetic acid [EDTA], pH 
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7.4)，pH7.4, 0.5% sodium dodecyl sulphate (Sigma, St. Louis, USA), and 
lOmg/ml Proteinase K (Sigma) was added to the de-paraffinized tissue and the 
resulting mixture was incubated at 55。C with rotation overnight for digestion of 
protein. Another aliquot of 10 ^il ofProteinase K was added for 2-3 more days to 
ensure complete digestion. Insoluble materials were removed by centrifogation 
and the lysate was divided into two 1.5 ml tubes, with about 400-500 ^1 each. 
Equal volume of phenol:chloroform:isoamyl alcohol (25:24:l),(v/v/v) was added 
to the lysate for extraction of protein. After centrifugation at 13000 rpm for 20 
minutes, the upper aqueous layer containing D N A was collected. D N A was then 
precipitated at —70。C for an hour after addition of one tenth volume of 3 M 
sodium acetate, pH 5.2，two volumes of chilled absolute alcohol and 10 ^il of 10 
mg/ml glycogen solution. The D N A pellet was washed twice with 100% ethanol， 
dried with a D N A Speed-Vac Concentrator (Savant Instruments Inc., 
Farmingdale, NY, USA), and resuspended in 10 ^il ofautoclaved MilliQ water. 
Commercially available DNA extraction kit 
In addition to the standard protocol, commercially available D N A 
extraction kit (Qiagen Inc.) was also applied. This kit simplified the procedures 
of D N A extraction and generated better quality of DNA. The steps for de-
paraffinization and protein digestion were similar to those of the standard 
protocol. After complete digestion of the tissues, the solution containing D N A 
was added into the spin column that is provided by the manufacturer. After 
centrifugation and washing twice with Buffer A W (wash buffer), the filtrate was 
discarded. D N A in the spin column was eluted twice with 10 ^1 autoclaved 
MilliQ water that had been preheated to 70°C. 
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ni.3.2. Extraction of Genomic DNA from Blood 
The frozen blood samples were thawed at 37¾ and then centrifuged at 
3500 rpm for 15 minutes to pellet the white cells. The cell pellets were then 
washed twice with IX phosphate buffered saline, pH 7.4 (Sigma) prior to 
Proteinase K digestion and phenol/chloroform extraction. Finally, the D N A was 
resuspended in autoclaved MilliQ water and stored at -20°C. 
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ni.4. Loss of Heterozygosity (LOH) Analysis 
on Chromosome 10q 
Currently, L O H analysis is the most widely used molecular genetic means 
of determining loss of genetic material. This analysis is based on detecting 
differences of the matemal and patemal alleles between normal constitutional 
D N A and tumor DNA. If a chromosomal locus is lost in a tumor, one ofthe two 
normal alleles will be absent in tumor D N A when compared with constitutional 
DNA. 
Microsatellite polymorphic markers containing simple repeat sequences 
are usually employed for L O H analysis. The most common types of 
microsatellites used are dinucleotide (CA)n repeats, where n varies from 10 to 60 
copies (Weber and May, 1989; Litt, 1991). (CA> repeats are plentiful 
throughout the human genome, approximately 50,000-100,000 separate {CA)n 
repeat sites are estimated to exist and are evenly distributed. Because of the 
variability in n, these markers are highly polymorphic. Allelic fragments can be 
amplified by PCR using sequence specific primers close to the dinucleotide 
repeats. Differences in the number of tandem (CA)n repeats between matemal 
and patemal alleles enable the two alleles to be easily identified after resolving 
them on denaturing polyacrylamide gel. 
Therefore, the (CA)« dinucleotide repeats method is superior to the 
traditional southern blotting technique, as the former is highly informative, rapid 
and simple to perform. As it is a PCR based method, even minute amount of 
DNA, such as that extracted from paraffin-embedded tissue sections is sufficient 
for detection. 
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ni.4.L Microsatellite Markers 
Nine microsatellite polymorphic dinucleotide markers (Table IIL4) on 
chromosome lOq were used in the L O H study. Four ofthe microsatellitemarkers 
flank the PTEN/MMAC1 regions, i.e., D10S215, D10S2491, D10S541 and 
D10S583，while the other five are mapped to chromosome 10q25-q26 regions. 
All of these polymorphic markers were purchased from Research Genetics, Inc. 
(Huntsville, AL, USA). 
Table EL4. Summary of the microsatellite markers used in LOH analysis. 
PCR conditions ^  
Markers Mapped Sizeof %of Annealing [DMSO] References� 
region PCR product Heterozygosity Temp. 
(base pairs) (�C) 
D10S215 10q23 152-208 0.81 55 5% [1，4，6，7] 
D10S2491 10q23 130-150 n.a. ^ 55 5% [ 2 ] ， 
D10S541 10q23 247-273 0.78 55 5% [4-7] 
D10S583 10* 201-219 0.84 53 / [5] 
D10S209 10q24-q26 181-216 0.75 60 5% [1，3,6，7] 
D10S587 10q24-q25 172-186 0.80 55 5% [1，3，6,7] 
D10S1723 10* 148-174 0.82 57 50/0 [3,7] 
D10S216 10q24-q26 202-225 0.61 53 / [1，3，7] 
D10S169 10q26 99-117 0.65 55 5% [1’8] 
• These markers have not been cytogenetically mapped. Recent studies have indicated their locations with 
respective to other markers used in this study, 
a n.a., not available. 
The PCR conditions used for amplification of target sequences were discussed in the text. 
CThe markers used have been reported previously: [1] Rasheed et al., 1995; [2] Caims et al., 1997. [3] 
Nagase et al., 1997; [4] Steck et al, 1997; [5] Wang et al” 1997; [6] Bostrom et al, 1998;'[7] IcWmura 
et al., 1998; [8] Peters et aL, 1998. 
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III.4.2. Amplification ofTarget Sequences bv PCR 
5 - end labeling of primers 
One of each primer pairs, usually the forward primer, was radioactively 
labeled prior to PCR. The end-labeling reaction mixture contained 0.2 pmole 
primer，1 i^Ci of [y-^^]-ATP (specific activity: 3000 Ci/mmole; Amersham, 
Buckinghamshire, UK), IX polynucleotide reaction buffer and 0.25 units of T4 
polynucleotide kinase (Amersham), in a total volume of 0.25 jixl. The reaction 
mixture was incubated at 37。C for 30 minutes. 
Amplification of target sequences 
PCR reactions were performed in a total volume of 5 jid containing 1 ^ 1 of 
genomic D N A extracted either from paraffin-embedded tissue or from normal 
blood sample, IX PCR buffer, 2 m M MgCl2, 62.5 jiiM deoxynucleoside 
triphosphate (dNTPs), 0.2 pmoles each of reverse primer and radioactively-
labeled forward primer and 0.625 unit of AmpliTaq Gold D N A polymerase 
(Perkin Elmer Cetus, Norwalk, CT). In some situations, 5% o f D M S O was added 
to the reaction mixtures to enhance specificity ofPCR. One drop ofmineral oil 
was added into each tube to prevent evaporation of samples during PCR. All 
PCR reagents were purchased from Perkin Elmer. 
The PCR was performed in a D N A thermal cycler (MJ Research, 
Watertown, M A , USA) with the following conditions: 95。C for 10 minutes to 
activate the AmpliTaq Gold D N A polymerase and forty cycles of amplification 
that consisted of 1 minute denaturation at 94。C，1 minute annealing at 53-60。C 
(as shown on Table 111.4)，1 minute extension at 72。C，followed by a final 10-
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minute extension step at 72°C. Ten microlitres stop buffer (95% formamide, 10 
m M E D T A O^H 8.0), 0.05% bromophenol blue, 0.05% xylene cyanol) was added 
to the PCR products which were then stored at 4°C until use. 
111.4.3. Denaturing Polvacrvlamide Gel Electrophoresis 
I 
6% polyacrylamide gel (with acrylamide:bisacrylamide = 29:1 (w/w), 
BioRad，Hercules California, USA) containing 7 M urea was prepared. Prior to 
sample loading, the gel was prewarmed for halfan hour in IX TBE (0.5 M Tris, 
0.5 M boric acid, 0.025 M EDTA) at 1650V. The PCR products were denatured 
at 95。C for about 10 minutes, quickly chilled on ice and 1-2 ^il ofPCR products 
was loaded onto the denaturing gel. Electrophoresis was carried out for 1.5 to 2.5 
hours, depending on the size of the PCR products. After electrophoresis, gels 
were transferred onto 3 M M Whatman papers (Springfield Mill, England) and 
vacuum dried using a gel dryer (BioRad, or Hoofer Scientific mstrurnents, San 
Francisco, CA，USA) for one hour at 80°C. The dried gels were then exposed to 
Kodak X - O M A T A R film (Eastman Kodak Company, Rochester, NY, USA) for 
1 day at room temperature. 
111.4.4. Detection ofLoss ofHeterozygositv (LOH) 
The analysis of allelic losses is based on comparsion of signal intensities 
ofthe matemal and patemal alleles between normal blood D N A and tumor DNA. 
Fluor-S ™ MultiImager (BioRad, Hercules, CA, USA) was employed to measure 
the allelic intensities. The matemal and patemal alleles were visualized as 2 
distinct bands on the autoradiograph. However, as slipped-strands mispairing 
sometimes occurred during PCR amplification, bands with weaker intensities 
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were occasionally observed. Nevertheless, the assessment of the allelic 
intensities was based on the signal intensities of the 2 major distinct bands. 
When the allelic intensities and patterns of the matemal and patemal alleles in 
both blood and tumor D N A were similar, this was referred as retained of 
heterozygosity (R). When the number ofCA dinucleotide repeats was similar or 
equal in both the matemal and patemal alleles, the 2 bands could not be 
distinguished and this was considered as non-informative (NI). L O H was 
inferred when there was at least 30% reduction in the band intensities in the 
tumor samples when compared with the corresponding blood samples (Koreth, 
0'Leary & McYee，1996). 
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n i . 5 . Mutational Analysis ofp53 and 
P T E N M M A C 1 
ni.5.1. Polymerase Chain Reaction-Single Strand Conformation 
Polymorphism fPCR-SSCP) Analvsis 
PCR-SSCP was used for mutation analysis. This technique is simple and 
powerful for identifying sequence changes in amplified D N A (Orita et al., 1989). 
It is based on the detection of electrophoretic mobility shift ofthe single-stranded 
D N A in nondenaturing polyacrylamide gels, probably because slight sequence 
changes have major effects on conformation. Thus wild-type and mutant genes 
are readily identified. As the conformational changes and the consequent 
alterations in electrophoretic mobility cannot be predicted, separation using 
several different conditions may be required to detect all mutations. 
IIL5.LL PCRPrimers 
Two genes,p55 and PTEN/MMAC1 were included for mutational analysis. 
Nested PCR was used in order to improve the specificity ofthe amplified target 
sequences. 
p53 
Exons 4-8 of the p53 gene were analyzed by nested PCR-SSCP. The 
sequences of both outer and inner primer pairs were presented in Table IIL5a. 
The oligonucleotide primers were synthesized from Oligos ETC, Inc. (Wilsaville, 
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Table III.5a. PCR conditions and primer sequences ofp53 used in PCR-SSCP 
analysis. 
PCR conditions 
Exons Product Annealing Temp. / Primer sequences ^ 
size (bp) No. of Cycles 
Outer primers  
4 446 50�C / fi 5,-CTGGGACCTGGAGGGCTGGG-3，  
^ r\ 5，-AGAGGAATCCCAAAGTTCCA-3， 
5 310 55�C / / : 5,-TGTTCACTTGTGCCCTGACT-3,  
^ r: 5,-AGCAATCAGTGAGGAATCAG-3, 
6 223 53°C / / : 5 '-TGGTTGCCCAGGGTCCCCAG-3，  
40 r. 5，-GGAGGGCCACTGACAACCA-3， 
~ ^ 59�C/ f . 5'-CTTGCCACAGGTCTCCCCAA-3'  
40 r: 5'- AGGGGTCAGCGGCAAGCAGA-3 ’ 
~ ^ Sf5 53°C/ f. 5'-TTGGGAGTAGATGGAGCCT-3'  
40 r: 5'-AGTGTTAGACTGGAAACTTT-3 ‘ 
Inner primers  
4 374 56�C/ f . 5'-CTGAGGACCTGGTCCTCTGAC-3'  
_ ^ r: 5,-ATACGGCCAGGCATTGAAGT -3， 
5 248 55�C/ / : 5'-TTCAACTCTGTCTCCTTCCT-3'  
40 r: 5,-CAGCCCTGTCGTCTCTCCAG-3， 
6 181 55�C / / : 5'-GCCTCTGATTCCTCACTGAT-3，  
^ n 5,-TTAACCCCTCCTCCCAGAGA-3, 
7 177 59�C / / : 5 '-AGGCGCACTGGCCTCATCTT-3,  
^ r: 5,-TGTGCAGGGTGGCAAGTGGC-3， 
8 231 55�C/ / : 5'-TTCCTTACTGCCTCTTGCTT-3' 
40 r: 5,-AGGCATAACTGCACCCTTGG-3， 
a/，forward primer sequences; r, reverse primer sequences. All the primer sequences have been 
described previously by Hsu et al, 1991 and Berg et al.，1995. 
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OR’ USA) and GibcoBRL Inc. (Gaithersburg, M D , USA). For exon 4，as the 
PCR fragment size was relatively large (>300 bp), two additional internal primers 
within the exon were designed, and they split the exon into two smaller 
overlapping fragments, each with a size of about 200 bp (Table m.5b). This 
makes amplification of PCR fragments easier as D N A that extracted from 
paraffin-embedded tissues were usually fragmented and degraded. 
PTENMMAC1 
Exons 1 to 9 of the PTEN/MMAC1 gene were analyzed by nested PCR-
SSCP. PTEN/MMA C7-specific PCR primers were synthesized from GibcoBRL 
Inc. according to the published sequences (Steck et al., 1997) (Table IIL6). 
/ / / . 5,1.2. PCR Amplification of Target Sequences 
p53 
Exons 4 to 8 of p53 were amplified by nested PCR. In the primary PCR, 
outer primer pairs were used. PCR reactions were performed in a total volume of 
25 ^ il containing 1 ^il of genomic D N A extracted from paraffin-embedded tissues, 
2.5 pmoles of each outer primer, 0.2 m M dNTPs, IX PCR buffer, 2.5 m M MgCl2 
and 0.75 units of AmpliTaq D N A polymerase (Perkin Elmer). A drop ofmineral 
oil was added into each tube prior to PCR. Thirty-five to forty cycles of 
amplification were performed with initial denaturation at 94°C for 30 seconds, 
annealing at 50-62^C for 1 minutes and extension at 72°C for 1 minute 
(annealing temperature and number of PCR cycles for each primer pairs were 
shown in Table III.5a & 5b). 
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Table III.5b. P C R conditions and sequences of2 additional internal primers for 
exon 4 ofp53 in PCR-SSCP analysis. 
Internal primers Sequences ^ 
Forward (JF) 5 '-GCACCAGCAGCTCCTACACC-3, 
Reverse (Dl) 5 ,-TGGGAAGGGACAGAAGATGA-3， 
PCR conditions 
Combination of Product size 
primers (bp) Annealing Temp. fC)>Wo. of Cycles 
Outer PCR 
Fragment 1: Outer f + JK 278 62�C/40 
Fragment 2: Outer r + W 241 60^C/40 
Inner PCR 
Fragment 1: Inner f + JR 246 60°C/40 
Fragment 2: Lrmer r + W 202 60°C/40 
a The sequences ofthe internal primers were designed using the software "OligoTech" 
(Oligos ETC, Inc.). 
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Table HL6. PCR conditions and primer sequences ofPTEN/MMACl used in 
PCR-SSCP analysis. 
PCR conditions 
Exon Annealing Temp. (�C)/ No. of Cycles Sequences ‘ 
1 54"C/35 Ofi 5'-CAGCCGTTCGGAGGATTA-3' 
> Or: 5'-ATATGACCTAGCAACCTGACCA-3' 
‘ 58°C/35 I/: 5'-AGTCGCTGCAACCATCCA-3' 
lr: 5'-TCTAAGAGAGTGACAGAAAGGTA-3' 
2 56�C/33 Ofi 5'-CCATGTGGAAGTTACCTTTTA-3‘ 
Or: 5 '-TACGGTAAGCCAAAAAATGA-3 ‘ 
56�C/33 I/: 5'-TGACCACCTTTTATTACTCCA-3' 
\r: 5'-TAGTATCTTTTTCTGTGGCTTA-3' 
3 54�C/35 Ofi 5'-ATATTCTCTGAAAAGCTCTGG-3， 
Or. 5'-TTAATCGGTTTAGGAATACAA-3' 
58�C/35 I/: 5'-ATAGAAGGGGTATTTGTTGGA-3' 
Ir : 5'-TCCTCACTCTAACAAGCAGATA-3' 
4 53�C/40 Of. 5 '-GGGGGTGATAACAGTATCTA-3 ‘ 
Or 5'-CTTTATGCAATACTTTTTCCTA-3 ‘ 
53"C/35 I/: 5'-TTCAGGCAATGTTTGTTA-3， 
lr ： 5'-TTCGATAATCTGGATGACTCA-3' 
5 56�C/40 Ofi 5'-AGTTTGTATGCAACATTTCTAA-3 ‘ 
Or: 5'-AGCAACTATCTTTAAAACCTGT-3 ‘ 
57�C/35 I/: 5'-GCAACATTTCTAAAGTTACCTA-3 ‘ 
lr: 5'-TCTGTTTTCCAATAAATTCTCA-3, 
6 540C/35 Ofi 5'-ATATGTTCTTAAATGGCTACGA-3' 
Or. 5 '-CTTTAGCCCAATGAGTTGA-3 ‘ 
58°C/35 I/: 5'-AGTTACCATAGCAATTTAGTGA-3‘ 
lr: 5'-TACATTGGAATAGTTTCAAACA-3' 
7 54�C/33 0/i 5'-ACAGAATCCATATTTCGTGTA-3 ‘ 
Or: 5'-TAATGTCTCACCAATGCCA-3' 
48�C/33 I/: 5'-ATCGTTTTTGACAGTTTG-3 ’ 
lr: 5'-TTCCCAATGAAAGTAAAGTACA-3 ‘ 
8 54"C/35 0/: 5'-TGCAAATGTTTAACATAGGTGA-3, 
Or. 5'-CGTAAACACTGCTTCGAAATA-3' 
58�C/35 I/: 5'-AGGTGACAGATTTTCTTTTTTA-3' 
Ir : 5 '-TAGCTGTACTCCTAGAATTA-3 ‘ 
9 54°C/35 Of. 5 '-CCTCTTAAAAGATCATGTTTG-3 ‘ 
Or: 5'-AGATTGGTCAGGAAAAGAGAA-3 ‘ 
50°C/35 I/: 5'-GTTCATCTGCAAAATGGA-3‘   
lr : 5，-TGGTAATCTGACACAATGTCCTA-3， 
a Of, outer forward primer; Or, outer reverse primer; l f , inner forward primer; Ir, inner reverse primer. 
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One microliter of 2-fold diluted primary PCR products were re-amplified 
using inner primer pairs. The composition ofthe nested PCR reaction mixtures 
was similar to that of the primary PCR except the addition of2.5 ^ Ci of [a-^ P^]-
dCTP (Amersham hic.). For exons 5 and 7，5% D M S O was also added into the 
reaction mixtures to enhance the specificity of PCR. PCR amplification was 
carried out for another 30-40 cycles with annealing temperatures ranging from 
55-60^C (annealing temperature and number of PCR cycles for each exon were 
shown in Table III.5a & 5b). 
PTENMMAC1 
Exons 1-9 of PTEN/MMAC1 were amplified using nested PCR. The 
composition ofreaction mixtures of primary PCR and nested PCR was similar to 
that for p53 except AmpliTaq Gold D N A polymerase (Perkin Ehner) was used 
instead. PCR conditions for PTEN/MMAC1 were as follows: heat activation of 
AmpliTaq Gold D N A polymerase at 95°C for 10 minutes, 33-40 cycles of 
denaturation at 94®C for 30 seconds, annealing at 48-58。C for 30 seconds and 
extension at 72°C for 40 seconds (Table IIL6). One microliter ofprimary PCR 
products were re-amplified using inner primers under similar PCR conditions as 
the primary PCR. 
III. 5.1.3. Non-denaturing Polyacrylamide Gel Electrophoresis 
Five microliters of nested PCR amplified products were mixed with 15 jul 
of stop buffer (95% formamide, 20 m M EDTA, pH 8.0，0.05% xylene cyanol, 
and 0.05% bromophenol blue), heat-denatured and resolved on a 6% or 8% non-
denaturing polyacrylamide gel (acrylamide:bisacrylamide = 49:1) with or without 
5% glycerol. Gels were run in 0.5X TBE at room temperature (2W) for 16-20 
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hours or at 4°C (30W) for 4-6 hours. After electrophoresis, gels were dried onto 
3 M M Whatman paper and exposed to Kodak X - O M A T A R film (Eastman Kodak 
Company) for 1-2 days at —70。C. Those cases with shifted band visualized on the 
autoradiographs were further analyzed by D N A sequencing to determine the 
nature of alterations. 
ni.5.2. Direct DNA Sequencing Analvsis 
D N A bands that displayed a mobility shift in the SSCP gel were cut out, 
and D N A was eluted in 50 ^ 1 of autoclaved MilliQ water by incubation at 65°C 
ovemight. 5 ^ il of eluted D N A was re-amplified with the corresponding sets of 
inner primers using the same conditions as described in III.5.1.2. The PCR 
products were resolved on a 10% polyacrylamide gel. D N A bands were then 
excised, extracted with phenol/chloroform and precipitated with absolute ethanol 
in the presence of 0.3M sodium acetate. The purified D N A was finally 
resuspended in 10 ^il of autoclaved MilliQ water. 
III. 5.2.1. Cycle Sequencing 
D N A sequencing was performed using the Thermosequenase cycle 
sequencing kit according to the manufacturer's instruction (Amersham Life 
Science Inc., Cleveland, OH, USA). Both the forward and reverse inner primers 
of the corresponding exon were 5'-end labeled with [y-^^P]-ATP by T4 
polynucleotide kinase in separate tubes, as described in IIL4.2. The labeled 
primers were subsequently diluted 2-fold with autoclaved distilled water. 1 ^il of 
diluted forward/reverse primer was separately mixed with 2^ il of purified DNA, 2 
|il ofreaction buffer and 8 units of Thermosequenase (as provided in the kit) in a 
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total volume of 17.5 ^il. 4 ^ il of the labeling mixture were transferred to each of 
the 4 termination tubes, labeled as A，G，C，and T，and each containing 4 ^ 1 of 
deoxynucleoside triphosphates (150 ^ iM dNTP) and dideoxyadenosine (1.5 ^ M 
ddA); dNTP and dideoxyguanosine (1.5 ^ iM ddG); dNTP and dideoxycytosine 
(1.5 ^ tM ddC); dNTP and dideoxythymidine (1.5 ^ iM ddT), respectively. The 
cycle sequencing reactions were carried out in a D N A thermal cycler using same 
conditions as described previously (IIL5.1.2.). 
/ / / . 5,2.2. Denaturing Gel Electrophoresis 
The reaction was stopped by adding 4 ^ 1 ofloading buffer (as provided in 
the kit). The PCR products were heat-denatured and 3 ^ il of each sample were 
loaded onto a 6% denaturing gel. The preparation of gels and the subsequent 
procedures for electrophoresis have been described in III.4.3. 
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III.6. Differential PCR for Detection oiMDM2 
Amplification 
Differential PCR is a semiquantitative, nonradioactive method for the 
detection of gene amplification. Differential PCR is particularly helpful in the 
analysis of tumor specimens that are archived, small in size and rare in 
occurrence. The basis of differential PCR is the co-amplification by PCR of a 
target gene and a reference gene in the same reaction tube. If the target gene 
copy number is greater than that of the reference gene, the PCR product of the 
target gene will be over-represented and the PCR amplification of the reference 
gene will be suppressed (Frye, Benz & Liu，1989). 
III.6.1. DNA Amplification bv PCR 
PCR was performed in a final volume of 25 i^l. Each reaction mixture 
contained 1-2 ^ il o f D N A template, 0.2 m M dNTPs, IX PCR buffer, 2.5 m M 
MgCl2, 2.5 pmoles ofprimers each for reference and target genes and 0.75 units 
of AmpliTaq Gold D N A polymerase (Perkin Elmer). The primers used were 
synthesized from GibroBRL, and dopamine receptor {DR) gene was used as the 
reference gene (Table IIL7). A malignant astrocytoma cell line，CCF-STTG1 
(obtained from American Type Culture Collection, Rockville, M D , USA), with 
known MDM2 gene amplification was used as a positive control. 
The PCR reaction was performed in a thermal cycler (MJ Research), with 
an initial enzyme activation step at 95°C for 10 minutes, followed by 28-33 
cycles of denaturation at 94°C for 30 seconds, annealing at 58°C for 1 minute and 
extension at 72°C for 1 minute. 
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Table III.7. Primers used for differential PCR. 
Gene Products size (bp) Primer sequences 
Target gene: 
MDM2 143 /: 5'-GAGGGCTTTGATGTTCCTGA-3' 
r: 5 '-GCTACTAGAAGTTGATGGC-3 ‘ 
Reference gene: 
dopamine receptor 113 /: 5 '-CCACTGAATCTGTCCTGGTATG-3， 
(DR) r: 5 ,-GTGTGGCATAGTAGTTGTAGTGG-3， 
/, forward primer; r, reverse primer. All the above primers have been reported previously 
(Hunter et al, 1995). 
III.6.2. Polyacrvlamide Gel Electrophoresis 
After PCR amplification, 25 ^ il of PCR products were mixed with 5 ^ il of 
6X stop buffer (0.25% bromophenol blue, 30% glycerol). An aliquot of8-12 ^ 1 
PCR products were electrophoresed on a 10% polyacrylamide vertical gel 
(acrylamide:bisacrylamide = 29:1). Fragments from cj)X174-HaeIII digested 
D N A were used as molecular weight markers. After running for 40 minutes, the 
gel was stained with 10 mg/ml ethidium bromide for about 15 minutes. The PCR 
bands were then visualized under U V illumination. 
III.6.3. Detection of Gene Amplification 
Gels were photographed using Polaroid film and the intensity of MDM2 
fragment (143 bp) and dopamine receptor reference sequence (113 bp) was 
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measured by means of a computer software "UVItech" (UVItec Ltd., Cambridge, 
UK). Density ratios ofthe target gene and the reference gene were determined in 
each lane. Ratio from normal brain tissues was also included (mean ratio = 1.25， 
SD = 0.19). The mean ratio 土 3SD (0.68-1.82) was considered as the range of 
normal ratio. Therefore, tumors with the ratio of MDM2/DR greater than 1.82 
were considered as having amplification ofthe MDM2 gene. 
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IV.1. LOH Analysis of Chromosome 10q 
Eighteen oligodendroglial tumors including seven oligodendrogliomas, 
seven anaplastic oligodendrogliomas and four oligoastrocytomas, and ten 
ependymomas were included in L O H analysis. D N A from paraffin-embedded 
tissues and the corresponding blood samples was used. Nine microsatellite 
markers were employed to study the allelic deletions on the PTEN/MMAC1 locus 
and 10q25-26 region on the long arm of chromosome 10. The results were 
shown on Figure IV.1. 
Among oligodendroglial tumors, all 18 cases were informative for at least 
one of the markers (D10S215, D10S2491, D10S541 and D10S583) flanking the 
PTEN/MMAC1 locus. Allelic deletions were observed in 4/7 (57%) informative 
oligodendrogliomas, 2/4 (50%) informative oligoastrocytomas and 3/7 (43%) 
informative anaplastic oligodendrogliomas. Allelic deletions on PTEN/MMAC1 
locus were detected in 5 out of 10 (50%) informative ependymomas. It was also 
noted that 1 oligodendroglioma, 3 anaplastic oligodendrogliomas and 2 
ependymomas had L O H at marker D10S2491, which was mapped within the 
PTEN/MMAC1 gene (Caims et al., 1997). The results suggest that 
PTEN/MMAC1 might be involved during anaplastic transformation in some cases 
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In oligodendroglial tumors, allelic deletions were found at loci flanking 
the PTEN/MMAC1 region (Figure IV.2). L O H was detected in 
oligodendrogliomas 0-PW24 at locus D10S215，in 0-PW8 at locus D10S541 and 
in 0-PW19 at locus D10S583. Allelic deletions were also found in 
oligoastrocytoma 0-BJ22 at locus D10S583 and in anaplastic oligodendroglioma 
0-PW27 at loci D10S215 and D10S2491. Allelic deletions on loci flanking the 
PTEN/MMAC1 regions were found in ependymomas E-PW23 at locus D10S215, 
E-PW20 at locus D10S2491，E-PW15 and E-PW19 at locus D10S541 (Figure 
TV3). Li oligoastrocytoma 0-PWll, L O H was observed in all the informative 
markers flanking the PTEN/MMAC1 regions (Figure IV.4). 
Allelic loss was also detected at chromosome 10q25-26 region in both 
oligodendroglial and ependymal tumors. All oligodendroglial and ependymal 
tumors were informative for at least one of the markers (D10S209, D10S587， 
D10S1723, D10S216 and D10S169) on the 10q25-26 regions. L O H was 
detected in 4/7 (57%) oligodendrogliomas, 1/4 (25%) oligoastrocytomas and 4/7 
(57%) anaplastic oligodendrogliomas. In ependymomas, L O H was observed in 
2/10 (20%) informative cases. 
It is believed that there are other putative tumor suppressor genes located 
at 10q25-26 region, between markers D10S587 and D10S216, that are important 
in the development of gliomas (Rasheed et al., 1995; Albarosa et al.’ 1996). 
Recently, a novel candidate tumor suppressor gene called DMBT1 localized to 
10q25.3-26.1, between D10S209 and D10S587 was identified (Mollenhauer et 
al., 1997). Li our study, allelic deletions on chromosomal region 10q25-26 were 
detected in all types of oligodendroglial tumors (Figure W,5). There were one 
oligodendrogliomas, 0-PW9 (Figure IV.6), and two anaplastic 
oligodendrogliomas, 0-PW20 (Figure IV.7) and 0-PW26 (Figure TV.S) that 
79 
Oligodendrogliomas 
Markers D10S215 D10S541 D10S583 
N T N T N T 
H H ； ~~~^  I F"“““^ 
國 一 i'":*"i-T 
^ ^ ^ ^ ^ ™ _ . fc^ »T,*S*^ .^ l 
Cases (0-PW24) (0-PW8) (0-PW19) 
Oligoastrocytoma Anaplastic oligodendroglioma 
Markers D10S583 D10S215 D10S2491 
N T N T N T 
- r H - ^ ^ 
Cases (0-BJ22) (0-PW27) (0-PW27) 
Figure FV.2. Representative results of LOH analysis in loci flanking the 
PTEN/MMAC1 region in oligodendroglial tumors. N, normal; 
T, tumor; arrows indicate allelic losses. 
108 
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Figure FV.3. Representative results of LOH analysis in loci flanking the 
PTEN/MMAC1 region in ependymal tumors. N, normal; T, 
tumor; arrows indicate allelic losses. 
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Figure WA. Results ofLOH analysis of oligoastrocytoma,, 0-PWll. N, normal; 
T, tumor; R, retain of heterozygosity; L, loss of heterozygosity 
(indicated by arrows); NI, non-informative. 
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Oligodendrogliomas 
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Figure FV.5. Representative results of LOH analysis at loci on chromosome 
10q25-26 in oligodendroglial tumors. N, normal; T, tumor; arrows 
indicate allelic losses. 
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Figure FV.6. Results of LOH analysis of oligodendroglioma, 0-PW9. N, normal; 
T, tumor; R, retain of heterozygosity; L, loss of heterozygosity (indicated 
by arrows). 
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Figure rV.7. Results ofLOH analysis of anaplastic oligodendroglioma, 0-PW20. 
N, normal; T, tumor; R, retain of heterozygosity; L, loss of 
heterozygosity (indicated by arrows); NI, non-informative. 
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Figure rV.8. Results ofLOH analysis of anaplastic oligodendroglioma, 0-PW26. 
N, normal; T, tumor; L, loss ofheterozygosity (indicated by arrows). 
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showed L O H in most of the informative markers studied at 10q25-26 region. In 
ependymomas, allelic deletion was also observed in E-PW24 and there was one 
ependymoma, E-PW12 that showed L O H in most ofthe informative markers at 
10q25-26 region (Figure IV.9). 
Table IV.1 showed the L O H frequency of all 28 non-astrocytic gliomas 
examined in this study using the 9 polymorphic microsatellite markers. L O H was 
found to be most frequent at markers D10S215 (75-100%) in both types ofnon-
astrocytic gliomas. Moreover, the frequency of allelic deletion at the telomeric 
end of chromosome lOq，between markers D10S216 (42%) and D10S169 (67%) 
was also high in oligodendroglial tumors. 
Besides allelic deletions, microsatellite instability was observed in both 
oligodendroglial and ependymal tumors. Microsatellite instability or replication 
error phenotype is usually associated with defects in D N A repair genes (Strand et 
al., 1993). In our study, microsatellite instability was found in 2 
oligodendrogliomas (0-PW8 and 0-PW19), 1 anaplastic oligodendroglioma 0-
PW27 (Figure IV.10) and 2 ependymomas, E-PW15 and E-PW19 (Figure 
rV.ll). It is worthwhile to note that most of the microsatellite instability 
occurred in loci at the chromosomal 10q25-26 region. 
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Figure rV.9. Representative results of LOH analysis at loci on chromosome 
10q25-26 in ependymomas. N, normal; T, tumor; arrows indicate 
allelic losses. 
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Table IV. 1 • Frequency o f L O H with 9 polymorphic markers on chromosome 
lOq in 28 non-astrocytic gliomas. 
Markers No. of cases No. ofinformative No. of % ofLOH 
studied cases LOH 
0 E 0 E 0 E 0 E 
D10S215 16 6 4 1 3 1 75 100 (80%) 
D10S2491 17 10 14 6 4 2 29 33 (30%) 
D10S541 17 9 5 5 1 2 20 40 (30%) 
D10S583 18 10 12 6 3 0 25 0 (17%) 
D10S209 16 7 13 4 3 0 23 0 (19%) 
D10S587 17 9 13 5 1 1 8 20 (11%) 
D10S1723 18 10 16 8 3 2 19 25 (21%) 
D10S216 18 10 12 5 5 1 42 20 (35%) 
D10S169 18 10 6 4 4 0 67 0 (40%) 
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I Figure W. 10. Representative results of LOH analysis showing microsatellite 
instability in oligodendroglial tumors. N, normal; T, tumor; 









t; Bj； I . 90 r 
Markers D10S583 D10S1723 D10S216 
N T N T N T 
r ~ ™  
Case l M ^ 1 mi 
E-PW19 P ^ ' :_ • _ I • ^ 
ftJ ! _ _ i < ——.:： 
l..,.,....— ^mm^i^. ^,*. titijij 
FigurerV.il. Results of LOH analysis showing microsatellite instability in 
ependymomas. N, normal; T, tumor; arrowheads indicate instability. 
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IV.2. Mutational Analysis ofp53 and 
PTENMMAC1 
Thirty-five oligodendroglial tumors and twenty-six ependymal tumors 
were examined foxp53 and PTEN/MMAC1 mutations. Exons 4 to 8 ofp53 and 
exons 1 to 9 of PTEN/MMAC1 were examined by PCR-SSCP. The results were 
summarized in Table IV.2a & b. 
In the PCR-SSCP analysis of p53, mobility shifts were found in 4/7 
oligoastrocytomas and 3/26 ependymomas. Direct sequencing of the aberrantly 
migrated D N A bands revealed changes of nucleotides in exons 4, 5, 7 and 8. 
Missense, frameshift，splicing and silent mutations were found in both 
oligoastrocytomas and ependymomas. Most of the mutations found were located 
in exon 4 (Figure IV.12). No mutations were found in other tumor subtypes, 
including oligodendrogliomas, anaplastic oligodendrogliomas, and anaplastic 
ependymomas. 
In oligoastrocytoma 0-PWll, a missense mutation was detected in exon 4 
of the p53 gene. A single base change was found at codon 98，leading to a 
change of amino acid residue from proline (CCT) to leucine (CTT). 
Oligoastrocytoma 0-BJ22 carried double mutations. Abnormal migration 
pattem was found in exon 5 (Figure IV.13). Sequencing analysis revealed a G to 
A transition at codon 161，leading to a change of amino acid from alanine (GCC) 
to threonine (ACC). In addition, a frameshift mutation caused by a 2 base-pair 
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Figure IV.12. Representative results ofPCR-SSCP analysis on exon 4 of pJJ in 
oligodendroglial and ependymal tumors. Altered migration patterns 
were found in an anaplastic ependymoma, E-PW5. Arrowheads 




s i g i 
:?¾?¾ o o o o 
T^ 
雪 专 • I 
- m m -
DNA Sequencing 
Normal Tumor 
A G C T A G C T 
^ f ^ I ^ C I A 
i\ S ？ yi 
^ � j f t A* Cj 4M» •• ^ k I ^ 
: z r i h ^ 
^ • LZ^ZJ 
Figure IV.13. Representative result of PCR-SSCP analysis of p53 gene in exon 5. 
Shifted bands are observed in tumor 0-BJ22. Sequencing analysis 
revealed a missense mutation at codon 161, GCC(Ala) 0 ACC (Thr). 
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Figure IV.14. Representative result of PCR-SSCP analysis on exon 4 of p53 
in oligodendroglial tumors. 0-BJ22 showed mobility shifts and 
sequencing analysis revealed a 2 base pairs insertion that leads 
to frameshifl mutation at codon 87. Arrows indicate aberrantly 
migrated bands; and asterisks indicate base pair insertion. 
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A single base substitution was detected at the intron 7/exon 8 splicing 
junction, four base pairs upstream of the coding sequence of exon 8 in 
oligoastrocytoma, 0-QE3. Mutations at the splicing site may lead to aberrant 
splicing and formation of non-functional protein during R N A processing. 
D N A sequence alteration that does not lead to changes in the amino acid 
coding sequence is referred as silent mutation. In 0-QE2，silent mutations were 
found at both codons 89 and 113 in exon 4. These silent mutations were resulted 
from the substitution of cytosine by thymine at the third position ofthe codon. 
Ependymoma E-PW10 exhibited mobility shift ofexon 4 (Figure IV.15). 
Direct sequencing showed a single base change from cytosine to thymine, 
resulting in a change of amino acid from proline (CCC) to leucine (CTC) at 
codon 89. In addition, a silent mutation was also found at codon 290 in exon 8. 
Silent mutations in exon 4 were also detected in one ependymoma E-PW5 
and one anaplastic ependymoma E-PW26. Such mutations occurred at the third 
position ofcodons 102 and 97，respectively, and both were C to T transitions. 
Constitutional D N A from those patients with silent mutations was not 
available to further verify if the sequence changes were D N A polymorphism. 
In summary, 43% (3/7) oligoastrocytomas and 4.2% (1/24) ependymomas 
harbored mutations in p53 which may lead to an altered and/or a non-functional 
p53 protein. Mutations at exon 4 were common and accounted for 60% (3 out of 
5) ofthe mutations that affected the encoded amino acid sequences. 
In the PCR-SSCP analysis ofPTEN/MMACI, no mutations were found in 
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Figure IV.15. Representative result of PCR-SSCP analysis on exon 4 of p53 
gene in ependymal tumors. E-PW10 showed abnormal banding 
patterns and sequencing analysis revealed a missense mutation 
at codon 89, CCC(Pro) <> CTC (Leu). Arrow indicates shifted 
bands; and asterisk indicates single base pair substitution. 
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the nine exons of PTEN/MMAC1 ofall oligodendroglial and ependymal tumors 
employed in this study (Figure IV.16). The results imply that this putative tumor 
suppressor gene does not play an essential role in the development ofthese non-
astrocytic gliomas. 
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FigureIV.16 . Representative results of PCR-SSCP analysis of PTEN/MMAC1 
at exons 2 and 3. No mobility shift was observed in all cases studied. 
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IV.3. Differential PCR Analysis ofMDM2 
Amplification 
Thirty-five oligodendroglial tumors and twenty-six ependymal tumors 
were examined for gene amplification ofMDM2 by differential PCR. In normal 
condition, the signal intensity ofboth target MDM2 gene and reference dopamine 
receptor {DR) gene was similar. D N A from normal brains was used as a normal 
control. A malignant astrocytoma cell line, CCF-STTG1, with an MDM2/DR 
mtio of 2.10 was used as a positive control. The normal range of MDM2/DR 
ratio was 0.68-1.82 (Mean 士 3 SD). Any tumors with ratio greater than 1.82 were 
considered as gene amplification of MDM2. The results were shown on Table 
W.3a & b. 
In the non-astrocytic gliomas examined in this study, only one 
ependymoma (E-PW15) showed amplification of the MDM2 gene (Figure 
rV.17). The ratio of MDM2/DR in this tumor was 2.14. Moreover, this 
ependymoma with MDM2 amplification did not carry a p53 mutation. Therefore， 
consistent with the results by Reifenberger et al. (1993) and Biemat et al (1997)， 
which reported that amplification of MDM2 was found in malignant gliomas 
without p53 mutations, it seemed that MDM2 amplification and p53 mutation 
were mutually exclusive in non-astrocytic gliomas that were included in this 
study. 
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Table IV.3a. Results ofMDM2 amplification in oligodendroglial tumors. 
Age/ Histo- Site of Amplification Ratio | 
Cases Sex pathology ^ Tumors^ ofMDM2/DR ‘ | 
Q ™ 2 ^ 1 0 cerebellum 0.96 """" 
0:gW2 AlfU 0 left frontal lobe Q.89 ~ 
Q : n ^ ^ J 6 M 0 left frontal lobe 0 '9T  
0-PW4 70/F AO corpus callosum — Q.97  
0-PW5 33/M 0 frontal lobe Q.84 | 
2±j^ 79/F 0 right temporal l o b e一 QJ8 
0-PW8 52M 0 left frontal lobe l.24 ~ | 
0-PW9 30M 0 right frontal lobe 一 om 
0-PW10 30/M 0 一 cerebellum — Q.82 | 
0 - P W l l 7M OA' 一 rightparietal lobe 0.98 
0-PW12 61/F AO • bifrontal lobe — Q.92  
0-PW13 20/F 0 temporal lobe — Q.84 I 
0-PW14 57/F OA' — righttemporal lobe 1.27 | 
0-PW15 70/M AO righthemisphere 0.99 | 
0-PW16 70/M AO left fronto-parietal lobe l.36 ~ | 
0-PW17 40fF AO ~ " right frontal lobe 0.94 | 
0-PW18 43/F OA' cerebellum l . l8 
0-PW19 35/M 0 parietal lobe 一 l.'l6  
0-PW20 42/F AO left frontal lobe 1.04 ~ | 
0::gW21 50/F QA' 一 corpus callosum l.l ~ 
0-PW23 60/M AO _ left frontal lobe 0.93 | 
0-PW24 29/M 0 left fronto-temporal lobe— 1.3 | 
0-PW25 40/M 0 frontal lobe 1:03 \ 
0-PW26 3SM AO right frontal lobe 一 0.87 | 
0-PW27 59M AO left frontal lobe 0.98 | 
0-PW28 58M AO 一 left frontal lobe f 5 i 
0-QEl 38/M 0 — n.a. “ l.21 | 
0-QE2 55/F OA: _ n.a. Q.93 j 
0-QE3 51FP OA' n.a. l.Q3 ~ 
0-QE4 43/F AO n.a. " I.13 | 
0-KWl 13/F 0 一 left occipital lobe 一 Q.71 | 
Q-KW2 18/F 0 left occipital lobe U 8 | 
0-AH208 29/M 0 ^ 0.7 J 
0-BJ22 一 16/F 一 OA^ 一 n.a. “ 0.99 ""j 
0-AUl 65/F AO 一 corpus callosum l.07 | 
a 0，oligodendroglioma ； AO, anaplastic oligodendroglioma; OA', oligoastrocytoma, compact type; 
OA^ oligoastrocytoma, diffuse type. 
^ n.a., not available. 
e Ratio greater than 1.82 was considered as MDM2 amplification. 
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Table IV.3b. Results ofMDM2 amplification in ependymal tumors. 
Age/ Histo- Site of AmplificationRatio 
Cases Sex pathology ^ Tumors^ ofMDM2/DR ^ 
E-PW2 25M E Wventricle ^ 
E-PW3 27/M E 一 n.a. _ 1.03 
E-PW4 4/F E W ventricle — 0.72 一 
E-PW5 25/M E right thalamus 1.19 
g:gW6 44/F E cauda equina U l 
E-PW7 69/F E r ^ 1.52 
E-PW8 60/M E spinal cord — 0 94 
E-PW10 38/F E cerebellum 1.01 一 
E-PW11 1/F E cerebrum 0.88 一 
E-PW12 7/F E rV ventricle 一 0.94 ~ 
E-PW13 31/F E - cerebellum — 0 88 一  
E-PW14 2 8 M E 一 spinal cord 1.15 
E-PW15 65fF E — spinal cord 2A4^ 
E-PW17 27/F E spinal cord — 1.5 
E-PW18 lQ/M E cervical cord 0.6 
E-PW19 22/F E posterior fossa 1.21 一 
g : g ^ ^ 17M E cerebellum 0.76 
E-PW21 12/F E 一 cerebellum — 0.89 ~ 
E-PW22 40/M E spinal cord 1.75 
E-PW23 45/F E spinal cord 1.43 _ 
E-PW24 39/F E 一 cauda equina 1.07 • 
E-PW25 8/T AE posterior fossa 1.43 
E-PW26 21M AE rightthalamus 1.11 — 
E-PW27 2/F E cerebrum 0.94 
E-PW28 T W E posterior fossa f o 5 
E-AH240 S M E n.a. U 4  
a E, ependymoma; AE, anaplastic ependymoma. 
�n.a., not available. 
^ Ratio greater than 1.82 was considered as MDM2 amplification. 
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Figure IV.17. Representative result of MDM2 gene amplification by differential 
PCR in oligodendroglial and ependymal tumors. The upper band 
(143 bp) represented MDM2 while the lower band (113 bp) was 
the reference dopamine receptor gene. CCF-STTG1, a malignant 
astrocytoma cell line, with MDM2 gene amplification, was used 
as a positive control. An ependymoma, E-PW15, showed MDM2 
gene amplification. 
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In summary, p53 and PTEN/MMAC1 do not play a major role in the 
development of oligodendroglial and ependymal tumors, p53 mutations were 
found in oligodendroglial tumors with astrocytic differentiation but not in other 
grades ofoligodendrogliomas (Table IV.4). This may suggest that mutations of 
P53 were associated with tumors with astrocytic components, as high frequency 
of p53 mutations (-30%) was observed in all grades of astrocytomas. In 
addition, amplification of MDM2 does not seem to be the target events of p53 
gene inactivation, as there was only one ependymoma showed MDM2 
amplification, which did not carry ap53 mutation (Table IV.4). 
In the L O H analysis, the frequency of allelic deletion were similar in 
10q23 and 10q25-26 regions in both oligodendroglial and ependymal tumors. 
However, more attention should be paid to oligodendroglial tumors as a high 
frequencies (42-75%) of L O H were detected at markers D10S215 (10q23), 
D10S216 (10q25-26) and D10S169 (10q26) (Table IV.1). This suggested that 
other tumor suppressor genes, yet unidentified, might be important in the 























































































































































































































In the past, histopathological parameters have been employed for the 
classification of brain tumors. However, while classical histopathological 
methods are not able to characterize pathogenic factors contributing to tumor 
formation in the brain, molecular genetic analyses have been applied to 
supplement the classical classification. Such molecular analysis has revealed 
frequent chromosomal alterations that may indicate specific molecular genetic 
mechanisms contributing to the development and prognosis of the brain tumors. 
The involvement of oncogenes and tumor suppressor genes in neoplastic 
disorders has now been firmly established (Bishop, 1991; Marshall, 1991). 
In contrast to astrocytic gliomas, the molecular oncogenesis in non-
astrocytic gliomas is rarely studied and is still poorly understood. In an attempt 
to explore the possible genetic factors involved in the development of non-
astrocytic gliomas, some of the common molecular events occurring during 
tumorigenesis of brain tumors were examined. In this study, we analyzed a 
cohort of 61 oligodendroglial and ependymal tumors for abnormalities of tumor 
suppressor genes p53 and PTEN/MMAC1, and also the MDM2 oncogene. In 
addition, 28 out of61 cases, where corresponding blood samples were available, 
were assessed for L O H on the long arm of chromosome 10. 
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v.l- p53 Gene Inactivation Studies 
P^3 is the nuclear phosphoprotein that plays a critical role in cellular 
growth and differentiation. In astrocytic gliomas, inactivation of p53, usually 
associated with mutations or loss of genetic materials, occurs in approximately 
one-third of astrocytomas, anaplastic astrocytomas and G B M (Louis, 1994; 
Bogler et al., 1995; Louis, 1997). It has been suggested that L O H 17p//?55 
mutation may be involved in an early stage of astrocytoma formation. Jn 
contrast, p53 mutations were rarely found in oligodendroglial tumors reported in 
three studies, with the frequency of2/17 (12%) in oligodendrogliomas (Ohgaki et 
“/•，1995), 6/44 (14%) in oligodendrogliomas, 4/19 (21%) in anaplastic 
oligodendrogliomas (Hagel et al., 1996)，1/25 (4%) in oligodendrogliomas and 
12/38 (32%) in oligoastrocytomas (Maintz et al； 1997). However, high 
percentage of p53 immunoreactivity (as high as 100% in anaplastic 
oligodendrogliomas) has been reported in oligodendrogliomas (Kros et al., 1993; 
Pavelic et al； 1994). The frequency of p53 protein expression was often found to 
be higher than that of p53 gene mutations (Mashiyama et cd., 1991; Fults et al” 
1992)，and some differences between p53 gene mutation and p53 protein 
expression exist. Positive p53 immunohistochemistry without the presence of a 
mutation may be due to an interruption of the normal degradative pathway ofp53 
(Kros et aL, 1993). In addition, p53 immunopositivity has also been observed in 
about 30% of oligoastrocytomas (Beckmann & Prayson，1997). These results 
suggested the accumulation of wild-type p53 protein in oligodendroglial tumors. 
In our study, p53 mutations were found exclusively in oligoastrocytomas, with 
mutation frequency of 3/7 (43%). This result is slightly higher than that of 
Maintz et cd., (1997) who reported p53 mutation in 12/38 (32%) of 
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oligoastrocytomas. As 2 out of 4 mutations found were in exon 4，and which was 
not examined in the three larger studies on oligodendroglial tumors (Ohgaki et 
“/.，1991; Hagel et al” 1996; Maintz et al., 1997)，this provides an explanation on 
the higher frequency of p53 mutations found in our study. However, no p53 
mutations were found in the 28 grade II and III oligodendrogliomas studied, but 
p53 was found to be mutated in 4-21% grade IWII oligodendrogliomas in 
previous studies (Ohgaki et aI., 1991; Hagel et aL, 1996; Maintz et al； 1997). 
Therefore, it appears that p53 mutations found in our series of oligodendroglial 
tumors are limited to those with significant astrocytic differentiation, and it seems 
that there is no difference between the compact type and diffuse type of 
oligoastrocytomas with regard to p53 mutations. As no p53 mutations were 
detected in 12 anaplastic oligodendrogliomas, it is suggested that p53 mutations 
do not play a significant role in the development and progression of 
oligodendrogliomas. 
In ependymomas, abnormalities of chromosome 17 have been examined in 
a few studies. Only ten cases of ependymomas have been reported with 
monosomy 17 so far, and 5 of them were found in pediatric patients (Stratton et 
a/.，1989; Griffin et al., 1992; Ransom et al； 1992a; Rogatto et al, 1993; 
Wemicke et al” 1995). Besides, a recent study (von Haken et al., 1996) has 
reported a 50% incidence of allelic losses on the short arm ofchromosome 17 in 
18 pediatric ependymomas. A few studies on p53 in ependymomas have been 
reported (Ohgaki et al., 1991; Fink et aL, 1996; Tominaga et al； 1995) and 
mutations of p53 have only been observed in 1/5 (20%) anaplastic ependymomas 
(Tominaga et al.，1995), but not in any grade II ependymomas examined so far. 
In our study, p53 mutation was found in 1 out of 24 (4.2%) grade II 
ependymomas but not in the 2 anaplastic (grade III) ependymomas, and this is the 
largest series that showed p53 mutations in ependymomas. Similar to what has 
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been observed in oligodendroglial tumors,j^5i mutation in ependymoma was also 
located in exon 4. As the number of cases studied so far remains very small, no 
conclusion can be drawn on the role of p53 in both initiation and anaplastic 
transformation of ependymomas. 
As the mutational inactivation of the p53 gene does not seem to take an 
active role in the tumorigenesis of these non-astrocytic gliomas, different 
mechanisms ofp53 gene inactivation are then taken into consideration. One of 
them is its interaction with the product ofthe MDM2 gene. The M D M 2 protein 
contains a p53 DNA-binding site and it can form a complex with p53. This, in 
tum, leads to the abolishment of the transcriptional activity of p53. Thus, this 
autoregulatory feedback loop normally regulates both the activities ofp53 protein 
and MDM2 expression (Picksley & Lane, 1993). An increase of p53 levels 
would block the entry into the cell cycle at late G1 checkpoint, this would induce 
the expression of M D M 2 , which then form complex with p53, and allow the 
entry into the S-phase of the cycle (Olson et al.，1993). Therefore, amplification 
or overexpression of M D M 2 provides a mechanism to escape from the p53-
regulated control of cell growth (Picksley and Lane, 1993). 
Amplification and overexpression of M D M 2 was found in 8-10% of 
human glioblastomas and anaplastic astrocytomas, but not in 18 
oligodendrogliomas and 8 ependymomas examined (Reifenberger et al” 1993). 
Besides, it was also found that glioblastomas with MDM2 amplification and 
overexpression carried no p53 mutations (Biemat et al” 1997)，suggesting that 
they are mutually exclusive events. Therefore, amplification and overexpression 
o f M D M 2 was an alternative mechanism of p53 inactivation. In our series of61 
non-astrocytic gliomas, only one ependymoma showed amplification of MDM2, 
suggesting that MDM2 gene amplification is also found not to be a major factor 
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for inactivation of the p53 gene. 
Wild-type p53 gene is known to cause cell cycle arrest in damaged cells at 
the G1 phase and induction of apoptosis in vitro (Clarke et al” 1993; Symonds et 
a/.，1994; Smith & Fomace, 1996). As the p53 gene is wild-type in most ofthe 
oligodendroglial and ependymal tumors studied in this series, it is believed that a 
relationship may exist between wild-type p53 and apoptosis in these non-
astrocytic gliomas. Another colleague in our team has therefore looked for the 
status of apoptosis in these tumors. The results demonstrated that the mean 
apoptotic index, which was obtained as a percentage of nuclei identified, of 
mutated tumors (0.025%) was less than that of the tumors with wild-type p53 
(0.5%). However, due to the generally low level of apoptosis in these tumors and 
the small number of p53 mutated samples (n = 4)，the difference was not 
statistically significant (data not shown). 
V.2. Molecular Genetic Studies on Chromosome 
10q 
With regard to malignant transformation in human gliomas, loss of 
heterozygosity on chromosome 10 was frequently detected, especially in 
glioblastoma multiformes (> 60%), the most malignant form of astrocytic gliomas 
(James et cd., 1988; Bigner & Vogelstein, 1990; Rasheed et aL, 1992; von 
Deimling et al, 1992b; Ye, W u & Darras，1993; Ohgaki et al., 1995). More than 
70% of glioblastomas show deletion of chromosome 10 which is often always 
associated with amplification of EGFR gene (von Deimling et al., 1992b; 
Kleihues and Ohgaki, 1997c). As von Deimling et al. (1992b) have shown that 
all cases with EGFR gene amplification always had L O H 10，it is tempting to 
speculate that the loss of a tumor suppressor gene or genes on chromosome 10 
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may precede EGFR gene amplification. Therefore, EGFR is suggested to play a 
role in glial tumorigenesis and progression. The role of EGFR was evaluated by 
an antisense E G F R model (Tian et al” in press). Suppression of EGFR 
expression in the antisense EGFR clones leads to significant inhibition of cell 
growth and transforming ability, and also induction of differentiation. This 
suggested that EGFR gene plays a major role in regulating cell proliferation and 
differentiation. Overexpression of EGFR is found in about half of both grade II 
and grade III oligodendrogliomas in the absence of EGFR gene amplification in 
most cases. The precise mechanism responsible for increased transcription of the 
EGFR gene in these tumors is unknown. As a result, loss of chromosome 10， 
together with EGFR abnormalities has been proposed to be the factors 
responsible for anaplastic transformation in oligodendrogliomas (Reifenberger et 
al., 1997). Besides, monosomy of chromosome 10 has been reported in 
ependymomas (Rey et al., 1987; Amoldus et al., 1992; Griffin et aL, 1992; 
Ransom et al., 1992a; Wernicke et al.，1995). In analogy to astrocytic gliomas, 
loss of chromosome 10 may represent the final step in the malignant progression 
ofboth oligodendroglial and ependymal tumors. 
Recently, two novel genes on chromosome 10q have been identified. One 
of them was localized to the proximal region of chromosome 10q at region 10q23 
while another was mapped to the distal end at chromosomal 10q25.3-26.1 region. 
The former gene was called PTEN (Li et al., 1997) or MMAC1 (Steck et aL, 
1997)，and the latter was called DMBT1 (Mollenhauer et al； 1997). Recent 
studies have shown PTEN/MMAC1 mutations in 23% anaplastic astrocytomas 
(Rasheed et al.，1997) and 25-44% glioblastomas (Liu et aL, 1997; Rasheed et 
al； 1997; Wang et al., 1997; Bostrom et al.，1998). DMBT1 was found to be 
deleted in malignant brain tumors, including 25% medulloblastomas and 59% of 
G B M primary tumors, but not in the ten lower-grade astrocytomas studied 
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(Mollenhauer et al” 1997). Mutational analysis ofDMBTl has not been reported 
so far. 
In contrast to astrocytic gliomas, PTEN/MMAC1 mutations in non-
astrocytic gliomas have been limited to two recent studies, which showed 
PTEN/MMAC1 mutations in none of 14 oligodendrogliomas (Rasheed et al., 
1997), 2 out of 22 oligodendrogliomas and none of 15 ependymomas examined 
(Duerr et al., 1998). In our study, allelic deletions at region flanking the 
PTEN/MMAC1 locus occurred at similar frequencies (43-57%) in all types of 
oligodendroglial and ependymal tumors for at least one of the markers examined. 
However, one of the markers, D10S2491, that was mapped to the 5'end within 
PTEN/MMACl was found to be lost in 1/7 (14%) informative 
oligodendrogliomas, 3/7 (43%) informative anaplastic oligodendrogliomas and 
2/10 (20%) informative ependymomas. This implied that part of the gene might 
be lost. As the frequency of allelic loss increased in anaplastic form of 
oligodendrogliomas, it is suspected that PTEN/MMACl may have a role in the 
progression of a subset of oligodendrogliomas. In addition to L O H analysis, 
PTEN/MMACl mutations were also assessed. However, no PTEN/MMACl gene 
mutations were detected in a total of 61 oligodendroglial and ependymal tumors 
examined. Therefore, inaetivation of PTEN/MMACl does not play an essential 
role in the majority of oligodendroglial and ependymal tumors. On the other 
hand, high frequency of L O H (75%) at marker D10S215 (Table IV.2) was 
observed in both oligodendroglial and ependymal tumors. W e suspect that 
another unidentified tumor suppressor gene might be harbored at region proximal 
to D10S215. However the number of informative cases for this marker is small, 
and larger number of cases is required to analyze before any conclusion can be 
drawn. 
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DMBT1 is located at distal 10q region, between markers D10S209 and 
D10S587 (Mollenhauer et al” 1997). L O H at region flanking the DMBT1 locus 
was found in about 11-19% (Table IV.2) ofall non-astrocytic gliomas examined 
for one ofthe 2 markers studied. As the frequency ofLOH was less than 30%, it 
was just considered as random allelic deletions by chance. Although it has been 
proposed that DMBT1 was deleted in malignant brain tumors, in our series, 
DMBT1 was not the target of malignant transformation in oligodendroglial and 
ependymal tumors. 
In addition to DMBT1, another closely related region has also been 
proposed to contain the glioblastoma suppressor locus on chromosome 10q25-26, 
between markers D10S587 and D10S216 (Rasheed et al., 1995; Maier et al； 
1997). Two out of four (50%) oligodendrogliomas have been found to display 
partial deletions on 10q25-26 (Maier et al,, 1997). Our results have also shown 
L O H between markers D10S587 and D10S216 in 2/7 (29%) oligodendrogliomas, 
3/7 (43%) anaplastic oligodendrogliomas and 2/10 (20%) ependymomas. 
Moreover, L O H at the telomeric end marker D10S169 accounted for as high as 
67% in oligodendroglial tumors (Table IV.2). These results suggested that in 
addition to DMBT1, another candidate glioma suppressor gene on the distal end 
of chromosome 10，between markers D10S587 and D10S216, may play a role in 
the progression of oligodendrogliomas. However, as the number of cases is too 
small, it is difficult to draw any concrete conclusion at this stage. 
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V.3. Microsatellite Instability in Non-Astrocytic 
Gliomas 
Microsatellite instability (MI) was initially observed in hereditary non-polyposis 
colon carcinoma (HNPCC) and colorectal cancer (Lindblom et al., 1993; 
Thibodeau, Bren & Schaid，1993). This instability can be observed as a change 
in the length of microsatellite sequences in tumor D N A as compared to 
constitutional DNA. Microsatellite shifts or presence of extra allele in tumors are 
to be considered as a strong indicator of microsatellite instability. Microsatellite 
instability is the result of replication errors, which is usually associated with 
defects in D N A repair genes. Mutations in the mismatch repair genes result in 
defective proteins that fail to correct replication errors, including those resulting 
from slippage during D N A replication. Previous studies have shown M I in 5.3% 
astrocytic gliomas (Dams et aL, 1995) and 0-3.2% in astrocytomas, 
meningiomas, schwannomas, pituitary adenomas and low-grade 
oligodendrogliomas (Zhu et aL, 1996). Recently, Zhu et aL (1998) has 
performed extensive screening of 16 oligodendrogliomas and 9 anaplastic 
oligodendrogliomas using 132 microsatellite markers on 19 different 
chromosomes. M I was exhibited in 1.7% oligodendrogliomas and 1% anaplastic 
oligodendrogliomas loci. In our study, 9 microsatellite markers on chromosome 
10q were used to study MI in 18 oligodendroglial tumors and 10 ependymomas. 
252 analyses (i.e., loci times samples) were performed and 138 of them were 
informative. The overall incidence of M I was 4/95 (4.2%) in oligodendroglial 
tumors, with 3/38 (7.9%) in oligodendrogliomas, 0/19 (0%) in oligoastrocytomas 
and 1/38 (2.6%) anaplastic in oligodendrogliomas, and 3/43 (7%) in 
ependymomas. The frequency of MI in our study is much higher than that 
reported by Zhu et aL (1998). The discrepancy may be due to their small number 
ofmarkers (n=3) studied on chromosome 10. 
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As in H N P C C and associated gastric, pancreatic and endometrial 
carcinomas, in which M I is implicated as an independent pathogenetic 
mechanism, the ratio of unstable loci to all investigated loci in any given sample 
is usually greater than 10% (Honchel, Hailing & Thibodeau，1995; Speicher, 
1995). In our study, the overall frequency ofMI was 4.2% in oligodendroglial 
tumors and 7% in ependymomas. Therefore, we conclude that M I is not an 
important pathogenetic mechanism for oligodendroglial and ependymal tumor 
development. 
V.4. Significance of This Study 
In astrocytic gliomas, p53 has been implicated to play an important role in 
both the initiation of lower grade tumors and progression towards a subset of 
glioblastomas, i.e., secondary glioblastomas. In addition, mutations of 
PTEN/MMAC1 have occurred at high frequency in both anaplastic astrocytomas 
and glioblastomas (described in 1.4.1). It was believed that non-astrocytic 
gliomas might follow similar genetic pathways involved in initiation and 
progression of tumors. In our series of oligodendroglial and ependymal tumors, 
we intended to analyze some of the genetic abnormalities that are commonly 
observed in astrocytic gliomas, such as p53 gene inactivation. However, our 
study revealed that p53 gene inactivation including p53 mutations and MDM2 
gene amplification did not seem to play an important role in the development of 
this series of tumors investigated except the oligoastrocytomas. Such findings 
may be important in the differential diagnosis of oligodendrogliomas and 
oligoastrocytomas. This is important as oligoastrocytomas have a survival less 
than oligodendrogliomas (Jaskolsky et al； 1987). Moreover, possible 
mechanisms concerning the malignant progression of these tumors were also 
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assessed. PTEN/MMAC1 and DMBT1 on the long arm of chromosome 10 were 
our target ofinvestigation. However, no PTEN/MMAC1 mutations were detected 
and allelic deletions of 10q23 and 10q25-26 appear to play only a role in the 
development ofsome oligodendroglial and ependymal tumors. 
V.5. Limitations of This Study 
Nevertheless, the methods applied and the materials used have brought out 
some limitations in this study. 
Sensitivity of SSCP 
SSCP is a powerful method for identifying sequence changes in amplified 
D N A . It is technically easy and is capable of screening large number of samples. 
However, the ability to detect mutations decreases for longer PCR products 
(optimal size < 220 bp). Gels should also be run at a constant controlled 
temperature as any temperature variations during electrophoresis can cause 
artifacts. Moreover, samples should be run on at least 2 gel systems in order to 
create a screening assay that can reliably detect 90-100% ofmutations in a given 
sequence. Thus, SSCP is considered as a screening technique rather than a 
definitive mean ofidentifying mutations (Fujita & Silver, 1994). Li addition, the 
gels are not always easy to interpret because of poor resolution and the presence 
of additional bands resulting from alternative conformations in unmutated 
sequences or the presence ofpartially denatured DNA. In some cases, bands of 
altered mobility may be faint, or the alteration in mobility may be minimal or 
blurred, and all these make interpretation become difficult (Warren et al., 1995). 
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Sensitivity ofLOH 
L O H is a successor to cytogenetic studies of chromosomal losses and has 
led to the identification of a multitude of chromosomal regions with nonrandom 
losses of genetic material in various types of neoplasm. However, L O H studies 
suffer from the need to test large panels of markers and to analyze the data by 
quantitation of band intensities. Most pathological tumor samples contain a 
mixture oftumor and non-tumor tissue, so that what one sees is often a decreased 
relative intensity, rather than total loss of the band from one allele. Besides, the 
percentage ofheterogeneity of some markers is low, i.e. smaller than 0.5, and this 
may lead to the generation of uninformative results. It is also difficult to tell how 
fine the region can be localized as the exact location of the markers may be not 
known. Even ifa fine region can be defined, it is not sure which potential tumor 
suppressor gene is actually involved as a lot of other unknown genes may also 
resided in the same region. 
Problems in histological diagnosis 
The histogenesis of oligoastrocytomas remains controversial. There is a 
lack of universally accepted, well-defined criteria for what percentage of the 
astroglial component needs to be present in order to designate a tumor as 
oligoastrocytoma. This relaxed criteria allows a degree of interobserver 
variability in oligoastrocytoma diagnosis (Maintz et al, 1997). Similar to 
oligoastrocytomas, the criteria adopted for classifying anaplastic ependymomas 
are vague. The presence ofmitoses, nuclear atypia and necrosis are considered as 
anaplasia of gliomas. However, they may not be necessarily indicative of 
malignancy in ependymomas (Rosenblum, Bibao & Ang，1996). 
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Problems in using archival tissues 
Brain tissue is usually stored for years at room temperature as formalin-
fixed paraffin-embedded (FFPE) tissue or in formalin. This provides an easy 
access to the large well-documented collections oftumors，especially convenient 
for obtaining those relatively rare tumors. However, due to the fixation process 
and age of the paraffin-embedded tissue, the D N A extracted may be degraded 
and fragmented，with a predominance ofDNA strands less than 300 base pairs in 
length (Jackson, Hayden & Quirke, 1991). Moreover, the presence ofinhibitory 
factors in the archival tissues may make PCR amplification difficult. It is 
important to note that certain mutations may be difficult to detect in archival 
tissues. For instance, Goodrow et al (1992) have shown that some C A A to CTA 
changes that can be identified in fresh tissues may not be detectable in FFPE 
tumors. It is possible, therefore, that our archival cases may harbor mutations 
that were not detected. 
Contamination with normal tissues 
It is common to find out that the brain tumor tissues are usually 
contaminated with a variable extent of normal brain tissues as gliomas are highly 
infiltrative lesions. As a result, some of the genetic abnormalities may then fail to 
be detected and the actual frequency involved may be under-estimated. 
Small sample size 
As oligodendroglial and ependymal tumors are relatively rare gliomas, the 
number of cases that obtained is relatively small, especially in oligoastrocytomas 
and anaplastic ependymomas. In addition, the small sample size employed in 
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molecular genetic analyses, e.g., in L O H studies, makes it difficult to draw a 
concrete conclusion. 
V.6. Future Studies 
Future studies can be focused on the following directions: 
(1) Improvement of materials used 
As I have mentioned before, the tumor tissues used are usually 
contaminated with normal tissue. This can be improved by separating the 
tumor and non-tumor tissues with the use ofmicrodissection technique, e.g., 
laser capture microdissection. In addition, as there is a lack of universally 
accepted criteria for the histopathological classification of oligoastrocytomas 
and anaplastic ependymomas, more clinicopathologic studies are required in 
order to provide a better definition ofhistological criteria ofthese two tumor 
types. 
(2) Extension of the present study 
Based on the results of this study, it is suggested that exon 4 ofp53 
gene should be extensively analyzed in the future mutational study ofp53. 
This region ofp53, which has been neglected in most ofthe previous studies, 
is found to be frequently mutated in our series of samples. Besides, 
mutational analysis of DMBT1 should be carried out once its genomic D N A 
sequence is released. Moreover, the results in L O H studies have shown that 
allelic deletions were frequent in regions proximal to D10S215 and between 
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D10S216 and D10S169. More markers should be used to focus on these 2 
distinct regions in an attempt to fine map the common deletion regions and if 
possible, the identification and positional cloning of the tumor suppressor 
genes involved. In addition，microsatellite instability was found in quite a 
number of cases in this study. This pathogenetic mechanism can be further 
investigated across the entire genome and to find out if it has a role in the 
development of non-astrocytic gliomas. 
(3) Application of other techniques 
In addition to the methods used in this study, many other 
techniques can be applied to detect genetic abnormalities from chromosomal 
to gene level. More cytogenetic studies should be performed to determine 
structural and numerical chromosomal abnormalities. These results can 
correlate with and supplement the molecular genetic data. Recently, 
comparative genomic hybridization (CGH) has also been applied for detecting 
genetic alterations. It is a power molecular cytogenetic technique that allows 
the detection of gains and losses of genetic materials over the genome at a 
resolution of 10-20 Mbp (Kallioniemi et al., 1992; du Manoir et al., 1993). 
This approach overcomes several limitations ofconventional karyotyping and 
allelotyping. By supplementing C G H with mutational analysis of the tumor 
suppressor gene known to be most frequently altered in gliomas, i.e., thep53 
gene，it is possible to obtain comprehensive information about the genetic 
changes involved in the development and progression ofgliomas. 
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